k141_128270_10	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	46.7	227	234	228	1.70e-67	206
k141_128270_10	CARD|gb|ATC67679.1|ARO:3000838|arlR	40.8	223	234	219	5.32e-59	184
k141_128270_10	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	42.2	225	234	231	2.18e-58	183
k141_128270_10	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	40.4	225	234	232	1.45e-56	179
k141_128270_10	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	40.1	227	234	232	1.16e-55	176
k141_128270_10	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	40.1	227	234	232	1.16e-55	176
k141_128270_10	CARD|gb|AAG05188.1|ARO:3005068|ParR	40.3	226	234	235	1.27e-55	176
k141_128270_10	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	40.1	232	234	235	2.54e-55	176
k141_128270_10	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	38.0	234	234	239	2.08e-52	168
k141_128270_10	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	40.2	229	234	231	3.72e-51	165
k141_128270_11	CARD|gb|AAD51347.1|ARO:3003067|smeS	26.9	271	471	467	2.60e-26	110
k141_128270_11	CARD|gb|CYF42523.1|ARO:3004047|kdpD	28.7	223	471	885	6.50e-21	95.1
k141_16244_1	SARG|gi|507044560|ref|WP_016115614.1|	37.1	194	195	306	5.52e-37	129
k141_16244_1	SARG|gi|500194536|ref|WP_011867743.1|	38.4	190	195	306	1.53e-36	128
k141_16244_1	SARG|gi|447195835|ref|WP_001273091.1|	38.9	190	195	306	2.15e-36	127
k141_16244_1	SARG|gi|488068784|ref|WP_002140181.1|	38.4	190	195	309	2.30e-36	127
k141_16244_1	SARG|gi|488053456|ref|WP_002124853.1|	37.9	190	195	309	4.54e-36	127
k141_16244_1	SARG|gi|447057509|ref|WP_001134765.1|	38.4	190	195	309	4.54e-36	127
k141_16244_1	SARG|gi|447195836|ref|WP_001273092.1|	38.4	190	195	306	5.98e-36	126
k141_16244_1	SARG|gi|446026113|ref|WP_000103968.1|	36.6	194	195	306	8.40e-36	126
k141_16244_1	SARG|gi|488067981|ref|WP_002139378.1|	37.9	190	195	309	8.95e-36	126
k141_16244_1	SARG|gi|507023808|ref|WP_016095885.1|	37.9	190	195	309	8.95e-36	126
k141_112402_7	SARG|gb|APB03219.1|ARO:3003986|TaeA	26.9	245	356	648	2.22e-16	79.3
k141_144417_25	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	32.1	215	420	307	8.22e-21	91.3
k141_144417_25	SARG|gi|542061059|gb|ERI11611.1|	28.7	279	420	316	2.29e-18	84.3
k141_144417_25	SARG|YP_001373621	28.7	209	420	318	9.60e-16	76.6
k141_144417_25	SARG|gb|AGN74946|ARO:3003749|salA	29.9	174	420	541	4.65e-13	69.7
k141_144417_25	SARG|gi|445983931|ref|WP_000061786.1|	29.0	214	420	492	1.77e-12	67.8
k141_144417_25	SARG|gi|1004356300|ref|WP_061531279.1|	29.0	214	420	492	3.13e-12	67.0
k141_144417_25	SARG|gi|487917313|ref|WP_001990779.1|	29.0	214	420	492	3.13e-12	67.0
k141_144417_25	SARG|gi|445983930|ref|WP_000061785.1|	29.0	214	420	492	3.13e-12	67.0
k141_144417_25	SARG|gi|445983932|ref|WP_000061787.1|	29.0	214	420	492	3.13e-12	67.0
k141_144417_25	SARG|gi|1008988570|ref|WP_061884457.1|	28.0	214	420	492	7.34e-12	65.9
k141_144417_34	NCBI|WP_016331865.1|1|1|vanA-Ao2|vanA-Ao2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-alanine--(R)-lactate_ligase_VanA-Ao2|AMR|glycopeptide	27.9	190	380	348	5.00e-11	62.4
k141_48434_3	SARG|EU408359.1.gene3.p01	27.8	151	210	300	2.03e-09	55.1
k141_48434_3	SARG|gb|AJP77080|ARO:3003720|SPG-1	25.3	154	210	285	1.10e-06	47.0
k141_48485_35	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	37.7	228	221	232	3.20e-46	152
k141_48485_35	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	37.7	228	221	232	3.20e-46	152
k141_48485_35	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	37.6	226	221	231	6.21e-46	151
k141_48485_35	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	38.5	226	221	231	1.24e-45	150
k141_48485_35	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	37.6	226	221	231	1.75e-45	150
k141_48485_35	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	37.6	226	221	231	1.75e-45	150
k141_48485_35	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	37.6	226	221	231	3.50e-45	149
k141_48485_35	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	35.7	224	221	231	5.55e-44	146
k141_48485_35	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	36.2	229	221	233	4.65e-43	144
k141_48485_35	SARG|ZP_02848503	37.4	219	221	221	1.05e-41	140
k141_48485_38	SARG|gi|851928815|ref|WP_048221086.1|	40.6	224	254	648	5.30e-50	172
k141_48485_38	SARG|gi|780033092|ref|WP_045444768.1|	40.6	224	254	648	5.30e-50	172
k141_48485_38	SARG|gi|974633183|ref|WP_059219858.1|	42.0	224	254	648	2.71e-49	170
k141_48485_38	SARG|gi|974684692|ref|WP_059267998.1|	42.0	224	254	648	2.71e-49	170
k141_48485_38	SARG|gi|643601187|ref|WP_025237288.1|	42.0	224	254	648	5.21e-49	169
k141_48485_38	SARG|gi|974628291|ref|WP_059215695.1|	42.0	224	254	648	5.21e-49	169
k141_48485_38	SARG|gi|446110298|ref|WP_000188153.1|	42.0	224	254	648	5.21e-49	169
k141_48485_38	SARG|gi|960873409|ref|WP_058345546.1|	39.3	244	254	648	5.21e-49	169
k141_48485_38	SARG|gi|555268037|ref|WP_023249477.1|	38.4	255	254	648	7.22e-49	169
k141_48485_38	SARG|gi|974672242|ref|WP_059256507.1|	42.0	224	254	648	1.00e-48	169
k141_32569_8	SARG|gb|AAK76137.1|ARO:3000024|patA	30.5	164	374	564	2.52e-15	76.3
k141_32569_8	SARG|gb|CDO61516.1|ARO:3003949|efrB	28.6	161	374	362	4.87e-13	68.6
k141_32569_8	SARG|gi|686436876|ref|WP_031922735.1|	25.8	194	374	491	7.20e-12	65.5
k141_32569_8	SARG|gb|AHB37625.1|ARO:3004715|vga(E)	28.4	194	374	524	7.45e-11	62.4
k141_32569_8	SARG|gi|686444151|ref|WP_031925491.1|	25.3	194	374	488	1.25e-10	61.6
k141_32569_8	SARG|FR772051.1.gene9.p01	27.4	208	374	524	1.32e-10	61.6
k141_32569_8	SARG|gi|581672381|gb|EVQ77821.1|	24.7	194	374	394	1.36e-10	61.2
k141_32569_8	CARD|gb|BAB80490.1|ARO:3007644|Cper_cplR	28.1	217	374	568	1.39e-10	61.6
k141_32569_8	SARG|gi|587321226|gb|EWW03298.1|	24.7	194	374	413	1.44e-10	61.2
k141_32569_8	SARG|gi|580336413|gb|EVD62957.1|	24.7	194	374	478	1.64e-10	61.2
k141_32569_17	SARG|gb|AAC74000.1|ARO:3003950|msbA	28.2	500	577	582	1.09e-60	210
k141_32569_17	SARG|gb|AAK76136.1|ARO:3000025|patB	29.1	492	577	588	1.16e-57	202
k141_32569_17	SARG|gi|953808775|ref|WP_058042812.1|	27.3	543	577	608	4.34e-57	201
k141_32569_17	SARG|gb|AYV52072.1|ARO:3002882|lmrD	27.9	548	577	664	2.01e-56	200
k141_32569_17	SARG|gb|CDO61516.1|ARO:3003949|efrB	34.1	273	577	362	2.19e-45	163
k141_32569_17	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	24.8	564	577	574	1.04e-43	163
k141_32569_17	SARG|gi|921979807|ref|WP_053271336.1|	27.0	222	577	648	1.56e-17	85.1
k141_32569_17	SARG|gb|AEA37904.1|ARO:3003112|lsaC	27.6	203	577	492	6.56e-09	57.4
k141_32569_17	SARG|FR772051.1.gene9.p01	24.8	206	577	524	1.58e-08	56.2
k141_32569_17	SARG|gb|AHB37625.1|ARO:3004715|vga(E)	26.6	192	577	524	1.11e-07	53.5
k141_32569_18	SARG|gi|928900436|ref|WP_053931243.1|	30.9	541	597	600	8.74e-69	233
k141_32569_18	SARG|gi|664579989|ref|WP_031094015.1|	30.9	541	597	601	8.93e-69	233
k141_32569_18	SARG|gi|860594225|ref|WP_048475168.1|	30.6	542	597	620	9.44e-69	233
k141_32569_18	SARG|gi|772774655|ref|WP_045322518.1|	30.8	542	597	620	1.31e-68	233
k141_32569_18	SARG|gi|926376632|ref|WP_053705806.1|	30.6	542	597	620	1.83e-68	232
k141_32569_18	SARG|gi|799286378|ref|WP_045936958.1|	30.4	542	597	620	4.91e-68	231
k141_32569_18	SARG|gi|917127754|ref|WP_051734466.1|	30.4	542	597	620	4.91e-68	231
k141_32569_18	SARG|gi|926294973|ref|WP_053631154.1|	30.4	542	597	620	4.91e-68	231
k141_32569_18	SARG|gi|926356413|ref|WP_053687351.1|	30.4	542	597	620	6.83e-68	231
k141_32569_18	SARG|gi|926345639|ref|WP_053677539.1|	30.4	542	597	620	6.83e-68	231
k141_945_10	SARG|gi|500194536|ref|WP_011867743.1|	34.1	302	304	306	6.54e-42	145
k141_945_10	SARG|gi|507055561|ref|WP_016126482.1|	33.1	278	304	309	1.48e-40	142
k141_945_10	SARG|gi|445996732|ref|WP_000074587.1|	33.8	278	304	309	4.08e-40	141
k141_945_10	SARG|P42332	33.1	290	304	306	5.33e-40	140
k141_945_10	SARG|gi|447057510|ref|WP_001134766.1|	33.1	278	304	309	5.72e-40	140
k141_945_10	SARG|AAD21213	32.8	290	304	306	1.47e-39	139
k141_945_10	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	32.8	290	304	306	1.47e-39	139
k141_945_10	SARG|gi|488053456|ref|WP_002124853.1|	32.7	278	304	309	1.58e-39	139
k141_945_10	SARG|gi|445996697|ref|WP_000074552.1|	33.5	278	304	309	1.58e-39	139
k141_945_10	SARG|gi|507023808|ref|WP_016095885.1|	33.1	278	304	309	1.58e-39	139
k141_945_13	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	33.6	220	237	293	2.03e-41	142
k141_945_13	SARG|gi|500194536|ref|WP_011867743.1|	35.7	213	237	306	1.17e-39	137
k141_80704_6	SARG|gi|488374619|ref|WP_002444004.1|	24.9	454	458	452	6.85e-33	128
k141_80704_6	SARG|HE999704.1.gene3064.p01	30.3	221	458	241	4.59e-27	107
k141_80704_6	SARG|gi|313614636|gb|EFR88215.1|	22.5	414	458	453	9.89e-22	96.3
k141_80704_6	SARG|gi|313638554|gb|EFS03703.1|	22.7	427	458	453	2.40e-21	95.1
k141_80704_6	SARG|HE999704.1.gene1126.p01	25.8	306	458	337	5.80e-16	77.8
k141_80704_6	SARG|gi|441473784|emb|CCQ23538.1|	26.1	307	458	336	8.15e-15	74.3
k141_80704_6	SARG|gi|441475675|emb|CCQ25429.1|	30.6	157	458	211	2.43e-14	70.9
k141_80704_6	SARG|gi|313619623|gb|EFR91268.1|	24.7	190	458	237	6.23e-12	64.3
k141_1192_6	SARG|gi|502669352|ref|WP_012905216.1|	39.5	220	229	648	3.79e-44	155
k141_1192_6	SARG|gi|803568669|ref|WP_046077412.1|	37.3	225	229	648	8.51e-41	146
k141_1192_6	SARG|gi|446110352|ref|WP_000188207.1|	37.3	225	229	648	8.51e-41	146
k141_1192_6	SARG|YP_002382193	37.3	225	229	648	8.51e-41	146
k141_1192_6	SARG|gi|803575554|ref|WP_046081557.1|	37.3	225	229	648	8.51e-41	146
k141_1192_6	SARG|gi|446110351|ref|WP_000188206.1|	37.3	225	229	648	8.51e-41	146
k141_1192_6	SARG|gi|757799695|ref|WP_043016897.1|	36.4	231	229	648	3.06e-40	144
k141_1192_6	SARG|gi|491270241|ref|WP_005128370.1|	36.8	220	229	648	3.06e-40	144
k141_1192_6	SARG|gi|851902043|ref|WP_048212057.1|	36.8	220	229	648	3.06e-40	144
k141_1192_6	SARG|gi|992380339|ref|WP_061067665.1|	36.8	220	229	648	3.06e-40	144
k141_49136_3	SARG|YP_002861121	50.7	71	212	212	1.08e-13	66.2
k141_49136_3	SARG|YP_001779894	54.3	70	212	212	1.04e-12	63.5
k141_49136_3	SARG|U19459.gene.p01	44.9	78	212	212	1.43e-12	63.2
k141_49136_3	SARG|YP_001389621	52.9	70	212	212	2.72e-12	62.4
k141_49136_3	SARG|YP_001785579	56.5	62	212	212	7.13e-12	61.2
k141_49136_3	SARG|M58472.1.gene1.p01	40.9	66	212	209	4.33e-10	56.2
k141_49136_3	NCBI|WP_031281281.1|1|1|catB|catB|acetyltransferase|2|CHLORAMPHENICOL|PHENICOL|type_B_phenicol_O-acetyltransferase|AMR|phenicol	38.5	65	212	210	4.38e-10	56.2
k141_49136_3	NCBI|WP_063856931.1|1|1|vat(E)|vat(E)|acetyltransferase|2|STREPTOGRAMIN|STREPTOGRAMIN|streptogramin_A_O-acetyltransferase_Vat(E)|AMR|streptogramin	29.8	161	212	214	6.28e-10	55.8
k141_49136_3	SARG|AAK91782	29.8	161	212	214	6.28e-10	55.8
k141_49136_3	SARG|ABF20240	50.0	58	212	210	8.24e-10	55.5
k141_49136_24	NCBI|XSG12259.1|1|1|drcR|drcR||1|||daptomycin_efflux_response_regulator_transcription_factor_DrcR|AMR|peptide	38.9	221	222	223	1.96e-51	165
k141_49136_24	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	31.7	227	222	229	4.55e-36	125
k141_49136_24	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	30.1	226	222	231	6.75e-36	125
k141_49136_24	CARD|gb|ADM92605.1|ARO:3000553|adeR	30.5	226	222	247	6.08e-34	120
k141_49136_24	CARD|gb|AAD51348.1|ARO:3003066|smeR	37.2	218	222	229	1.09e-33	119
k141_49136_24	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	28.4	229	222	233	3.99e-31	113
k141_49136_24	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	29.7	232	222	252	9.98e-29	107
k141_49136_24	CARD|gb|AAG05188.1|ARO:3005068|ParR	29.2	226	222	235	1.03e-27	104
k141_49136_26	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	56.9	255	256	255	7.48e-103	298
k141_49136_26	SARG|gi|896325272|ref|WP_049294291.1|	40.6	224	256	648	1.54e-51	176
k141_49136_26	SARG|gi|639216333|ref|WP_024554080.1|	40.6	224	256	648	1.54e-51	176
k141_49136_26	SARG|gb|AAV85982.1|ARO:3000535|macB	38.9	229	256	644	2.04e-51	176
k141_49136_26	SARG|gi|974588181|ref|WP_059178476.1|	41.1	224	256	646	7.76e-51	174
k141_49136_26	SARG|gi|1032819400|ref|WP_064325534.1|	41.1	224	256	646	7.76e-51	174
k141_49136_26	SARG|YP_001176128	41.4	222	256	646	1.08e-50	174
k141_49136_26	SARG|gi|657888313|ref|WP_029592374.1|	40.6	224	256	648	1.53e-50	174
k141_49136_26	SARG|gi|639225329|ref|WP_024561799.1|	40.6	224	256	648	2.12e-50	173
k141_49136_26	SARG|gi|639218559|ref|WP_024556062.1|	40.6	224	256	648	2.12e-50	173
k141_49136_27	NCBI|XSG12257.1|1|1|drcB|drcB||1|||daptomycin_efflux_ABC_transporter_permease_DrcB|AMR|peptide	23.9	687	679	641	3.71e-39	152
k141_49136_28	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	39.9	223	223	231	1.18e-46	153
k141_49136_28	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	36.8	223	223	232	1.21e-46	153
k141_49136_28	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	36.5	230	223	232	4.31e-44	146
k141_49136_28	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	36.5	230	223	232	4.31e-44	146
k141_49136_28	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	33.9	224	223	231	3.72e-42	141
k141_49136_28	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	33.5	224	223	231	2.94e-41	139
k141_49136_28	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	34.9	218	223	228	7.62e-41	138
k141_49136_28	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	33.5	224	223	231	1.17e-40	137
k141_49136_28	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	33.2	226	223	230	2.26e-40	137
k141_49136_28	CARD|gb|ATC67679.1|ARO:3000838|arlR	32.6	218	223	219	2.37e-40	136
k141_49136_29	SARG|gi|542061059|gb|ERI11611.1|	44.0	302	305	316	3.54e-80	244
k141_49136_29	SARG|P42332	43.4	302	305	306	7.37e-80	243
k141_49136_29	SARG|ABB80128	43.4	302	305	306	1.04e-79	243
k141_49136_29	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	43.6	298	305	306	1.48e-79	243
k141_49136_29	SARG|gi|510143239|gb|AGN36970.1|	43.6	298	305	313	1.83e-79	243
k141_49136_29	SARG|AAD21213	43.0	302	305	306	1.18e-78	240
k141_49136_29	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	43.3	300	305	307	1.22e-78	240
k141_49136_29	SARG|ZP_04081918	43.4	302	305	306	4.75e-78	239
k141_49136_29	SARG|gi|447195835|ref|WP_001273091.1|	43.4	302	305	306	6.72e-78	238
k141_49136_29	SARG|gi|446026113|ref|WP_000103968.1|	43.4	302	305	306	9.50e-78	238
k141_49136_31	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	27.2	250	297	370	5.12e-17	79.3
k141_49136_31	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	25.8	236	297	365	1.68e-16	77.8
k141_49136_31	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	24.0	296	297	381	6.22e-16	76.3
k141_49136_31	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	24.0	296	297	381	6.22e-16	76.3
k141_49136_31	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	24.6	313	297	381	2.09e-15	74.7
k141_49136_31	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	24.6	313	297	381	2.09e-15	74.7
k141_49136_31	CARD|gb|ACM47284.1|ARO:3002934|vanS_in_vanD_cl	26.4	148	297	233	6.28e-06	45.4
k141_49136_31	megares|MEG_7508|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	26.4	148	297	233	6.28e-06	45.4
k141_49136_36	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	34.8	112	719	232	9.72e-13	67.4
k141_49136_36	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	31.3	112	719	231	4.74e-11	62.4
k141_49136_36	CARD|gb|ATC67679.1|ARO:3000838|arlR	31.6	114	719	219	1.32e-10	60.8
k141_49136_36	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.2	118	719	219	4.37e-10	59.3
k141_49136_36	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.2	118	719	219	4.37e-10	59.3
k141_49136_36	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.2	118	719	220	4.44e-10	59.3
k141_49136_36	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.2	118	719	220	5.99e-10	58.9
k141_49136_36	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	31.4	118	719	220	3.60e-09	56.6
k141_49136_36	CARD|gb|AAG06465.1|ARO:3005063|cprR	30.8	120	719	223	4.07e-08	53.5
k141_49136_38	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	27.6	228	983	359	8.69e-20	91.3
k141_49136_38	CARD|gb|ADM92606.1|ARO:3000549|adeS	26.3	247	983	361	1.68e-18	87.4
k141_49136_38	CARD|gb|AAC75429.1|ARO:3000833|evgS	35.1	114	983	1197	1.04e-11	68.2
k141_49136_38	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.1	114	983	219	4.26e-11	62.8
k141_49136_38	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.1	114	983	219	4.26e-11	62.8
k141_49136_38	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.1	114	983	220	4.33e-11	62.8
k141_49136_38	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.1	114	983	220	5.84e-11	62.4
k141_49136_38	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	28.7	122	983	232	1.87e-09	58.2
k141_49136_38	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.3	114	983	220	3.88e-09	57.0
k141_49136_38	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	25.4	126	983	231	4.50e-09	57.0
k141_1330_9	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	32.2	115	123	232	7.69e-13	61.6
k141_1330_9	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	32.1	112	123	232	1.48e-12	60.8
k141_1330_9	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	32.0	103	123	225	3.56e-10	54.3
k141_1330_9	CARD|gb|AAC73788.1|ARO:3003841|kdpE	32.0	103	123	225	3.56e-10	54.3
k141_1330_9	CARD|gb|AAD51348.1|ARO:3003066|smeR	30.5	82	123	229	1.27e-08	50.1
k141_1330_19	SARG|Q52360	27.1	457	529	641	5.44e-34	135
k141_1330_19	SARG|Q08425	26.7	457	529	641	4.42e-33	132
k141_1330_19	NCBI|WP_063856408.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	26.7	457	529	654	4.71e-33	132
k141_1330_19	megares|MEG_7181|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	26.7	457	529	657	4.78e-33	132
k141_1330_19	SARG|Z21523.gene.p01	26.7	457	529	657	4.78e-33	132
k141_1330_19	megares|MEG_7182|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	26.7	457	529	670	5.06e-33	132
k141_1330_19	SARG|AAB51122	26.7	457	529	670	5.06e-33	132
k141_1330_19	NCBI|WP_063856409.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	26.7	457	529	641	3.55e-32	129
k141_1330_19	SARG|P70882	26.7	457	529	641	3.55e-32	129
k141_1330_19	SARG|AAZ79478	26.7	457	529	657	3.82e-32	129
k141_1332_31	SARG|gb|AAO04716.1|ARO:3002865|dfrC	35.1	148	162	161	1.08e-25	95.1
k141_1332_31	NCBI|WP_012655890.1|1|1|dfrE|dfrE|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrE|AMR|diaminopyrimidine	31.9	160	162	164	1.84e-24	92.0
k141_1332_31	SARG|gb|AAA25550.1|ARO:3003105|dfrA3	34.5	148	162	162	2.73e-23	89.0
k141_1332_31	ResF|dfrE_1_CP080326_1	31.2	125	162	128	1.29e-15	68.2
k141_1332_31	SARG|gb|AHV80711.1|ARO:3002863|dfrA8	31.5	168	162	169	6.67e-13	62.0
k141_1332_31	SARG|gb|AAK64581.1|ARO:3004568|dfrA18	29.6	135	162	184	4.95e-06	43.5
k141_1332_36	NCBI|WP_000420313.1|1|1|msr(D)|msr(D)|target_protection|2|AZITHROMYCIN/ERYTHROMYCIN/STREPTOGRAMIN_B|MACROLIDE/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_Msr(D)|AMR|multidrug	23.7	541	519	487	1.26e-13	72.0
k141_1332_36	SARG|gi|500194536|ref|WP_011867743.1|	28.6	203	519	306	2.64e-13	69.7
k141_1332_36	NCBI|WP_000420317.1|1|1|msr(D)|msr(D)|target_protection|2|AZITHROMYCIN/ERYTHROMYCIN/STREPTOGRAMIN_B|MACROLIDE/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_Msr(D)|AMR|multidrug	24.1	540	519	487	2.11e-12	68.2
k141_1332_36	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	23.2	211	519	293	4.59e-11	62.8
k141_1332_36	SARG|gb|WP_082039181.1|ARO:3007028|salD	25.1	191	519	544	6.81e-11	63.5
k141_1332_36	SARG|gb|SOX29786.1|ARO:3004730|tva(A)	23.0	196	519	505	3.43e-10	61.2
k141_1332_36	NCBI|WP_014936356.1|1|1|tva(B)|tva(B)|target_protection|2|TIAMULIN|PLEUROMUTILIN|ABC-F_type_ribosomal_protection_protein_Tva(B)|AMR|pleuromutilin	22.8	197	519	504	1.84e-09	58.9
k141_1332_36	SARG|gi|664556405|ref|WP_031071225.1|	21.4	234	519	602	3.33e-08	55.1
k141_1332_36	NCBI|WP_000052512.1|1|1|msr(E)|msr(E)|target_protection|2|AZITHROMYCIN/ERYTHROMYCIN/STREPTOGRAMIN|MACROLIDE/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_Msr(E)|AMR|multidrug	22.8	426	519	491	3.89e-08	54.7
k141_1332_36	SARG|gi|948137056|ref|WP_056795395.1|	23.9	209	519	602	1.01e-07	53.5
k141_1332_51	SARG|gi|1028848471|ref|WP_064017434.1|	33.3	84	186	206	5.68e-14	66.2
k141_1332_51	SARG|gi|670466162|ref|WP_031414939.1|	38.6	70	186	206	2.11e-13	64.7
k141_1332_51	SARG|gi|515720450|ref|WP_017153050.1|	39.5	81	186	210	2.24e-13	64.7
k141_1332_51	SARG|AF155139.2.gene5.p01	40.0	70	186	206	4.06e-13	63.9
k141_1332_55	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.7	518	545	655	1.97e-71	239
k141_1332_55	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.5	518	545	655	2.74e-71	239
k141_1332_55	SARG|gb|AKA86814|ARO:3003746|optrA	30.5	518	545	655	2.74e-71	239
k141_1332_55	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.7	518	545	655	3.82e-71	239
k141_1332_55	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.5	518	545	655	7.42e-71	238
k141_1332_55	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.5	518	545	655	7.42e-71	238
k141_1332_55	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.5	518	545	655	7.42e-71	238
k141_1332_55	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.5	518	545	655	7.42e-71	238
k141_1332_55	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.5	518	545	655	1.03e-70	238
k141_1332_55	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.5	518	545	655	1.03e-70	238
k141_145688_1	megares|MEG_7571|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	36.3	353	356	451	1.21e-63	208
k141_145688_1	megares|MEG_7572|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	35.5	349	356	481	2.44e-63	208
k141_145688_1	megares|MEG_7563|Drugs|Glycopeptide|VanB-type_resistance_protein|VANXB_2	35.2	349	356	451	1.84e-62	205
k141_145688_8	NCBI|WP_063852710.1|1|1|mecB|mecB|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecB|AMR|beta-lactam	27.2	404	455	674	4.48e-23	101
k141_145688_8	SARG|gb|BAI83385.1|ARO:3003440|mecB	27.7	405	455	674	5.99e-23	100
k141_145688_22	SARG|gi|754927849|ref|WP_042284850.1|	38.7	300	899	648	4.26e-51	189
k141_145688_22	SARG|YP_001571041	37.5	299	899	648	1.06e-50	188
k141_145688_22	SARG|gi|749017716|ref|WP_040076354.1|	37.6	298	899	646	4.64e-50	186
k141_145688_22	SARG|gi|960873409|ref|WP_058345546.1|	37.1	299	899	648	6.45e-50	186
k141_145688_22	SARG|gi|654544841|ref|WP_028012549.1|	37.8	296	899	646	1.55e-49	185
k141_145688_22	SARG|gi|754951242|ref|WP_042307417.1|	37.2	298	899	648	1.59e-49	185
k141_145688_22	SARG|gi|696361545|ref|WP_032936694.1|	36.6	298	899	648	1.59e-49	185
k141_145688_22	SARG|gi|740610794|ref|WP_038396317.1|	37.1	299	899	648	1.59e-49	185
k141_145688_22	SARG|gi|493734654|ref|WP_006683876.1|	36.9	298	899	648	1.59e-49	185
k141_145688_22	SARG|gi|1031822889|ref|WP_064150402.1|	36.8	296	899	646	2.09e-49	184
k141_145688_24	SARG|gi|488321355|ref|WP_002390740.1|	26.3	205	310	492	1.00e-08	55.1
k141_145688_24	SARG|gi|488231473|ref|WP_002302681.1|	25.4	205	310	492	1.00e-08	55.1
k141_145688_24	SARG|gi|488216250|ref|WP_002287458.1|	25.4	205	310	492	1.00e-08	55.1
k141_145688_24	SARG|gi|488247627|ref|WP_002318835.1|	25.4	205	310	492	1.00e-08	55.1
k141_145688_24	SARG|AY004350.gene.p01	25.4	205	310	492	1.00e-08	55.1
k141_145688_24	SARG|gi|488243106|ref|WP_002314314.1|	24.9	205	310	492	1.33e-07	51.6
k141_145688_24	SARG|gb|APB03219.1|ARO:3003986|TaeA	38.7	62	310	648	6.22e-07	49.7
k141_145688_24	SARG|gb|AVI44920.1|ARO:3004470|poxtA	23.8	210	310	542	3.22e-06	47.4
k141_145688_24	NCBI|WP_209691075.1|1|1|poxtA2|poxtA|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA2|AMR|multidrug	23.8	210	310	544	3.22e-06	47.4
k141_145688_24	NCBI|WP_002294513.1|1|1|lsa(E)|lsa(E)|target_protection|2|LINCOSAMIDE/STREPTOGRAMIN|LINCOSAMIDE/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_Lsa(E)|AMR|multidrug	23.0	200	310	494	4.12e-06	47.0
k141_146149_4	CARD|gb|WKR28567.1|ARO:3007678|IreK	28.4	201	342	718	1.04e-17	83.2
k141_18266_8	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.3	309	317	655	1.65e-53	184
k141_18266_8	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.3	309	317	655	1.65e-53	184
k141_18266_8	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.0	309	317	655	6.10e-53	182
k141_18266_8	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.0	309	317	655	6.10e-53	182
k141_18266_8	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.0	309	317	655	6.10e-53	182
k141_18266_8	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.0	309	317	655	6.10e-53	182
k141_18266_8	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.0	309	317	655	6.10e-53	182
k141_18266_8	SARG|gb|AKA86814|ARO:3003746|optrA	34.0	309	317	655	6.10e-53	182
k141_18266_8	megares|MEG_4323|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.0	309	317	655	1.17e-52	182
k141_18266_8	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	33.7	309	317	655	4.34e-52	180
k141_146333_7	CARD|gb|ABD30512.1|ARO:3000839|arlS	33.3	222	562	451	4.24e-30	122
k141_146333_7	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	29.3	239	562	392	1.60e-24	104
k141_146333_7	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.6	234	562	381	4.05e-22	97.4
k141_146333_7	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.6	234	562	381	4.05e-22	97.4
k141_146333_7	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.2	234	562	381	3.22e-21	94.7
k141_146333_7	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.2	234	562	381	3.22e-21	94.7
k141_146333_7	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	25.4	256	562	370	4.08e-20	91.3
k141_146333_7	CARD|gb|AAD51347.1|ARO:3003067|smeS	28.8	236	562	467	5.01e-19	89.0
k141_146333_7	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	24.1	224	562	365	1.78e-18	86.3
k141_146333_7	CARD|gb|CYF42523.1|ARO:3004047|kdpD	24.9	217	562	885	4.87e-15	77.4
k141_146333_8	CARD|gb|ATC67679.1|ARO:3000838|arlR	41.3	223	224	219	8.65e-47	153
k141_146333_8	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	38.2	225	224	228	4.46e-46	151
k141_146333_8	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	36.5	230	224	231	6.84e-43	143
k141_146333_8	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	38.8	232	224	235	1.08e-42	143
k141_146333_8	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	36.5	230	224	231	1.93e-42	142
k141_146333_8	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	36.5	230	224	231	2.72e-42	142
k141_146333_8	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	38.4	219	224	219	2.76e-42	141
k141_146333_8	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	38.4	219	224	220	2.84e-42	141
k141_146333_8	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	41.3	230	224	231	3.84e-42	141
k141_146333_8	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	41.3	230	224	231	3.84e-42	141
k141_146570_13	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	33.3	135	350	228	2.09e-15	73.6
k141_146570_13	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	33.6	119	350	231	4.85e-14	69.7
k141_146570_13	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	33.1	136	350	231	1.22e-13	68.6
k141_146570_13	CARD|gb|ADM92605.1|ARO:3000553|adeR	34.7	124	350	247	2.07e-13	68.2
k141_146570_13	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	33.1	136	350	231	2.26e-13	67.8
k141_146570_13	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	33.8	136	350	231	7.69e-13	66.2
k141_146570_13	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	34.9	126	350	231	1.04e-12	65.9
k141_146570_13	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	34.5	113	350	232	1.06e-12	65.9
k141_146570_13	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	34.5	113	350	232	1.06e-12	65.9
k141_146570_13	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	34.8	115	350	230	1.18e-11	62.8
k141_146570_14	CARD|gb|AAD51348.1|ARO:3003066|smeR	27.8	115	893	229	2.63e-06	48.5
k141_146570_15	CARD|gb|AAC75429.1|ARO:3000833|evgS	30.7	391	892	1197	2.91e-46	179
k141_179446_13	SARG|gb|WP_104671188.1|ARO:3003948|efrA	36.1	562	587	575	9.93e-112	344
k141_179446_13	SARG|gb|AAK76137.1|ARO:3000024|patA	34.8	528	587	564	1.08e-95	302
k141_179446_13	SARG|gb|AAC74000.1|ARO:3003950|msbA	30.7	531	587	582	1.13e-73	245
k141_179446_13	SARG|gi|739906046|ref|WP_037756452.1|	31.3	518	587	620	3.96e-65	223
k141_179446_13	SARG|gi|1033217078|gb|OAR27197.1|	30.6	526	587	601	7.35e-65	222
k141_179446_13	SARG|gi|516574297|ref|WP_017949361.1|	31.3	517	587	620	7.63e-65	222
k141_179446_13	SARG|gb|AAK76136.1|ARO:3000025|patB	28.5	495	587	588	2.12e-64	220
k141_179446_13	SARG|gi|1045390184|ref|WP_065479071.1|	30.1	501	587	605	2.96e-64	220
k141_179446_13	SARG|gi|928900436|ref|WP_053931243.1|	32.1	505	587	600	3.73e-64	220
k141_179446_13	SARG|gi|664579989|ref|WP_031094015.1|	32.1	505	587	601	3.81e-64	220
k141_179446_14	SARG|gb|AYV52072.1|ARO:3002882|lmrD	36.2	516	608	664	1.54e-96	308
k141_179446_14	SARG|gb|AAK76136.1|ARO:3000025|patB	32.1	585	608	588	1.32e-90	290
k141_179446_14	SARG|gb|AAC74000.1|ARO:3003950|msbA	32.5	514	608	582	8.32e-85	275
k141_179446_14	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	32.6	577	608	579	9.05e-82	267
k141_179446_14	SARG|gb|CDO61516.1|ARO:3003949|efrB	42.5	346	608	362	6.40e-80	255
k141_179446_14	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	30.9	583	608	579	2.03e-78	258
k141_179446_14	SARG|gi|748767925|ref|WP_040019608.1|	33.4	584	608	623	1.11e-76	254
k141_179446_14	SARG|gi|943909899|ref|WP_055545300.1|	33.0	584	608	601	1.02e-74	249
k141_179446_14	SARG|gi|860594225|ref|WP_048475168.1|	30.3	591	608	620	1.10e-74	249
k141_179446_14	SARG|gi|817122037|ref|WP_046494699.1|	33.2	570	608	613	2.57e-74	248
k141_18890_17	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	34.2	225	912	255	1.25e-38	143
k141_18890_17	SARG|gi|742384718|ref|WP_038863845.1|	41.9	222	912	647	1.30e-37	149
k141_18890_17	SARG|gi|696420214|ref|WP_032990021.1|	41.4	222	912	647	5.50e-37	147
k141_18890_17	SARG|YP_001438541	41.4	222	912	647	7.34e-37	147
k141_18890_17	SARG|gi|938461734|ref|WP_054625806.1|	41.4	222	912	647	7.34e-37	147
k141_18890_17	SARG|gi|938460528|ref|WP_054624864.1|	41.4	222	912	647	7.34e-37	147
k141_18890_17	SARG|gi|1020141879|ref|WP_063264839.1|	41.4	222	912	647	7.34e-37	147
k141_18890_17	SARG|gi|490522515|ref|WP_004387938.1|	41.4	222	912	647	7.34e-37	147
k141_18890_17	SARG|gi|494938585|ref|WP_007664615.1|	41.4	222	912	647	7.34e-37	147
k141_18890_17	SARG|gi|742378414|ref|WP_038857601.1|	41.4	222	912	647	7.34e-37	147
k141_18890_18	SARG|gi|1045390184|ref|WP_065479071.1|	30.5	573	578	605	4.50e-96	304
k141_18890_18	SARG|gi|497748188|ref|WP_010062372.1|	30.5	573	578	605	8.88e-96	303
k141_18890_18	SARG|gi|664170108|ref|WP_030704355.1|	30.9	573	578	603	1.66e-95	303
k141_18890_18	SARG|gi|490068471|ref|WP_003970646.1|	30.9	573	578	603	1.66e-95	303
k141_18890_18	SARG|gi|501350226|ref|WP_012381861.1|	30.9	573	578	603	3.28e-95	302
k141_18890_18	SARG|gi|764446018|ref|WP_044369325.1|	30.4	573	578	605	4.85e-95	301
k141_18890_18	SARG|gi|663330365|ref|WP_030329892.1|	30.9	573	578	607	7.17e-95	301
k141_18890_18	SARG|gi|664042835|ref|WP_030582300.1|	30.5	573	578	604	9.33e-95	301
k141_18890_18	SARG|gi|951183771|ref|WP_057661487.1|	30.2	573	578	603	1.28e-94	300
k141_18890_18	SARG|gi|827013130|ref|WP_047175495.1|	30.7	573	578	603	1.79e-94	300
k141_18890_39	ResF|mre(A)_1_U92073_1	33.4	293	303	310	8.94e-55	179
k141_18890_39	SARG|gb|AAB64408.1|ARO:3007050|mreA	33.4	293	303	311	9.18e-55	179
k141_18890_56	SARG|gb|AAK76137.1|ARO:3000024|patA	28.4	218	230	564	2.80e-13	67.4
k141_18890_70	megares|MEG_7409|Drugs|Glycopeptide|VanA-type_resistance_protein|VANHA_2	33.2	253	349	293	1.12e-32	122
k141_18890_70	SARG|AAY52005	28.3	350	349	343	1.14e-32	123
k141_18890_70	SARG|gi|1002798395|gb|AMN85478.1|	25.9	351	349	343	3.86e-28	111
k141_243782_6	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	34.4	224	253	255	4.28e-35	125
k141_243782_6	SARG|gi|542061059|gb|ERI11611.1|	31.2	237	253	316	8.04e-26	102
k141_243782_6	SARG|gb|AAK76137.1|ARO:3000024|patA	31.2	234	253	564	4.71e-18	82.0
k141_243782_6	SARG|gb|CDO61516.1|ARO:3003949|efrB	26.2	202	253	362	1.46e-16	77.0
k141_211498_5	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	30.3	99	238	228	8.70e-07	47.4
k141_211498_5	CARD|gb|ATC67679.1|ARO:3000838|arlR	28.7	108	238	219	1.10e-06	47.0
k141_132696_4	NCBI|WP_063856862.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	26.8	265	398	356	1.31e-17	82.4
k141_84672_5	SARG|gi|1004359922|gb|AMP42228.1|	26.5	434	606	639	6.01e-29	120
k141_84672_5	megares|MEG_7169|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	26.0	435	606	629	4.35e-28	118
k141_84672_5	megares|MEG_7170|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	26.0	435	606	629	4.35e-28	118
k141_84672_5	ResF|tet(O/W)_3_AM889120_1	26.0	435	606	639	4.52e-28	118
k141_84672_5	ResF|tet(O/W)_4_AM889121_1	26.0	435	606	639	4.52e-28	118
k141_84672_5	megares|MEG_7163|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	26.0	435	606	629	5.80e-28	117
k141_84672_5	ResF|tet(O/W)_5_AM889122_1	26.0	435	606	639	6.03e-28	117
k141_84672_5	megares|MEG_7174|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	25.7	435	606	629	1.83e-27	116
k141_84672_5	ResF|tet(O/W)_2_AM889119_1	25.7	435	606	639	1.90e-27	116
k141_84672_5	megares|MEG_7173|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	25.7	435	606	629	2.45e-27	115
k141_244842_9	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.2	520	572	655	7.67e-99	313
k141_244842_9	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.2	520	572	655	1.08e-98	312
k141_244842_9	SARG|gb|AKA86814|ARO:3003746|optrA	35.2	520	572	655	1.08e-98	312
k141_244842_9	megares|MEG_4323|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.2	520	572	655	2.12e-98	311
k141_244842_9	megares|MEG_4319|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.2	520	572	655	2.98e-98	311
k141_244842_9	megares|MEG_4321|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.2	520	572	655	4.18e-98	311
k141_244842_9	megares|MEG_4317|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.2	520	572	655	4.18e-98	311
k141_244842_9	megares|MEG_4314|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.2	520	572	655	4.18e-98	311
k141_244842_9	megares|MEG_4311|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.2	520	572	655	4.18e-98	311
k141_244842_9	megares|MEG_4305|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.2	520	572	655	4.18e-98	311
k141_148524_2	CARD|gb|AAG06465.1|ARO:3005063|cprR	33.8	77	239	223	5.52e-08	50.8
k141_85044_17	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	27.8	209	881	232	2.49e-14	72.4
k141_85044_17	CARD|gb|ADM92605.1|ARO:3000553|adeR	25.7	245	881	247	3.53e-13	69.3
k141_85044_17	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	29.1	151	881	231	2.24e-12	66.6
k141_85044_17	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	28.5	123	881	220	1.64e-07	52.0
k141_85044_17	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	28.5	123	881	219	2.18e-07	51.6
k141_85044_17	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	28.5	123	881	219	2.18e-07	51.6
k141_85044_17	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	28.5	123	881	220	2.21e-07	51.6
k141_85044_17	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	28.5	123	881	220	2.97e-07	51.2
k141_133653_3	SARG|gi|500194536|ref|WP_011867743.1|	38.9	190	197	306	4.19e-37	129
k141_133653_3	SARG|gi|447195835|ref|WP_001273091.1|	39.5	190	197	306	5.90e-37	129
k141_133653_3	SARG|gi|507044560|ref|WP_016115614.1|	38.4	190	197	306	8.29e-37	129
k141_133653_3	SARG|gi|447195836|ref|WP_001273092.1|	38.9	190	197	306	1.64e-36	128
k141_133653_3	SARG|gi|488068784|ref|WP_002140181.1|	38.9	190	197	309	2.45e-36	127
k141_133653_3	SARG|gi|542061059|gb|ERI11611.1|	38.4	190	197	316	2.84e-36	127
k141_133653_3	SARG|gi|488053456|ref|WP_002124853.1|	38.4	190	197	309	4.84e-36	127
k141_133653_3	SARG|gi|447057509|ref|WP_001134765.1|	38.9	190	197	309	4.84e-36	127
k141_133653_3	SARG|ZP_04081918	38.4	190	197	306	6.38e-36	126
k141_133653_3	SARG|gi|446026113|ref|WP_000103968.1|	37.9	190	197	306	8.97e-36	126
k141_38105_6	megares|MEG_8639|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|POXT_1	31.3	201	205	543	6.06e-29	111
k141_38105_6	NCBI|WP_094899500.1|1|1|poxtA-Ef|poxtA-Ef|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA-Ef|AMR|multidrug	31.3	201	205	543	6.06e-29	111
k141_38105_6	ResF|poxtA-Ef_1_WP094899500.1_1	32.3	195	205	538	8.12e-29	111
k141_38105_6	NCBI|WP_171943877.1|1|1|vga(F)|vga(F)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(F)|AMR|lincosamide	47.7	65	205	461	8.85e-11	59.3
k141_38105_6	NCBI|WP_172065992.1|1|1|vga(F)|vga(F)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(F)|AMR|lincosamide	46.2	65	205	461	1.62e-10	58.5
k141_38105_6	NCBI|WP_000052512.1|1|1|msr(E)|msr(E)|target_protection|2|AZITHROMYCIN/ERYTHROMYCIN/STREPTOGRAMIN|MACROLIDE/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_Msr(E)|AMR|multidrug	40.3	67	205	491	4.54e-09	54.3
k141_38105_6	NCBI|AKC61310.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	52.1	48	205	552	2.85e-08	52.0
k141_38105_6	NCBI|AJP12342.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	38.6	57	205	550	3.84e-08	51.6
k141_38105_6	CARD|gb|BAB80490.1|ARO:3007644|Cper_cplR	47.9	48	205	568	1.28e-07	50.1
k141_38105_6	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	41.5	65	205	655	1.33e-07	50.1
k141_118077_10	SARG|gb|WP_104671188.1|ARO:3003948|efrA	37.5	573	579	575	3.23e-114	350
k141_118077_10	SARG|gb|AAK76137.1|ARO:3000024|patA	30.8	568	579	564	1.90e-84	273
k141_118077_10	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	31.3	387	579	574	5.77e-53	189
k141_118077_10	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	31.6	392	579	579	3.87e-50	181
k141_118077_10	SARG|gi|928900436|ref|WP_053931243.1|	33.7	362	579	600	6.79e-49	178
k141_118077_10	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	31.9	389	579	579	6.86e-49	177
k141_118077_10	SARG|gi|664579989|ref|WP_031094015.1|	33.7	362	579	601	6.89e-49	178
k141_118077_10	SARG|gi|1045390184|ref|WP_065479071.1|	33.8	364	579	605	7.29e-49	178
k141_118077_10	SARG|gi|497748188|ref|WP_010062372.1|	33.1	362	579	605	1.00e-48	177
k141_118077_10	SARG|gi|664180077|ref|WP_030714054.1|	33.1	362	579	605	4.89e-48	176
k141_118077_11	SARG|gb|AAK76136.1|ARO:3000025|patB	35.8	531	578	588	1.62e-103	323
k141_118077_11	SARG|gb|AYV52072.1|ARO:3002882|lmrD	37.2	516	578	664	9.14e-102	321
k141_118077_11	SARG|gb|CDO61516.1|ARO:3003949|efrB	44.6	354	578	362	1.61e-91	285
k141_118077_11	SARG|gi|496018010|ref|WP_008742581.1|	31.7	540	578	623	3.54e-79	260
k141_118077_11	SARG|gi|926351744|ref|WP_053683383.1|	31.0	538	578	648	2.41e-77	256
k141_118077_11	SARG|gi|860594225|ref|WP_048475168.1|	30.3	538	578	620	3.58e-77	255
k141_118077_11	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	31.8	484	578	578	1.45e-76	252
k141_118077_11	SARG|gi|944009777|ref|WP_055601444.1|	29.0	572	578	628	1.62e-76	253
k141_118077_11	SARG|gi|917203192|ref|WP_051809904.1|	30.3	538	578	620	2.66e-76	253
k141_118077_11	SARG|gi|917229923|ref|WP_051836635.1|	30.9	538	578	620	2.66e-76	253
k141_118077_12	SARG|gi|1028848471|ref|WP_064017434.1|	28.2	131	191	206	1.11e-10	57.4
k141_118077_12	SARG|gi|515720450|ref|WP_017153050.1|	32.1	131	191	210	1.61e-10	57.0
k141_118077_12	SARG|AF155139.2.gene5.p01	37.1	116	191	206	5.52e-10	55.5
k141_118077_12	SARG|gi|670466162|ref|WP_031414939.1|	28.2	124	191	206	1.32e-08	51.6
k141_118077_12	NCBI|WP_063856927.1|1|1|vanZ-Pt|vanZ-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_protein_VanZ-Pt|AMR|glycopeptide	34.0	100	191	159	2.32e-06	44.7
k141_118077_13	SARG|gi|447195835|ref|WP_001273091.1|	33.3	312	315	306	3.33e-46	157
k141_118077_13	SARG|ZP_04081918	42.2	211	315	306	4.68e-46	157
k141_118077_13	SARG|gi|542061059|gb|ERI11611.1|	34.4	311	315	316	6.01e-46	157
k141_118077_13	SARG|gi|445996719|ref|WP_000074574.1|	42.7	211	315	309	7.09e-46	156
k141_118077_13	SARG|gi|447195836|ref|WP_001273092.1|	33.0	312	315	306	9.24e-46	156
k141_118077_13	SARG|gi|445996710|ref|WP_000074565.1|	41.7	211	315	309	2.76e-45	155
k141_118077_13	SARG|gi|895736250|emb|COF64653.1|	41.7	211	315	309	1.08e-44	153
k141_118077_13	SARG|gi|446110087|ref|WP_000187942.1|	41.7	211	315	309	1.08e-44	153
k141_118077_13	SARG|gi|445996714|ref|WP_000074569.1|	41.7	211	315	309	1.08e-44	153
k141_118077_13	SARG|gi|445996723|ref|WP_000074578.1|	42.2	211	315	309	1.08e-44	153
k141_118077_17	SARG|gb|CAE00499.1|ARO:3003835|cdeA	35.3	434	449	441	1.67e-97	298
k141_7278_10	SARG|gi|639216333|ref|WP_024554080.1|	42.8	229	246	648	2.13e-54	184
k141_7278_10	SARG|gi|896325272|ref|WP_049294291.1|	42.4	229	246	648	5.72e-54	182
k141_7278_10	SARG|gi|1005616587|ref|WP_061695226.1|	44.4	216	246	648	7.96e-54	182
k141_7278_10	SARG|gi|695701476|ref|WP_032638992.1|	44.4	216	246	646	1.08e-53	182
k141_7278_10	SARG|gi|555268037|ref|WP_023249477.1|	43.5	216	246	648	1.11e-53	182
k141_7278_10	SARG|gi|924626178|ref|WP_053530123.1|	43.5	216	246	648	1.11e-53	182
k141_7278_10	SARG|gi|981224618|ref|WP_059445588.1|	44.9	216	246	646	2.08e-53	181
k141_7278_10	SARG|gi|895872463|ref|WP_048979698.1|	44.4	216	246	646	2.08e-53	181
k141_7278_10	SARG|gi|836585048|ref|WP_047742322.1|	44.9	216	246	646	2.08e-53	181
k141_7278_10	SARG|gi|922019548|ref|WP_053299973.1|	43.5	216	246	648	2.14e-53	181
k141_7278_15	SARG|gb|CAE00499.1|ARO:3003835|cdeA	26.0	438	464	441	3.76e-34	132
k141_7278_15	SARG|HE999704.1.gene3064.p01	29.7	202	464	241	6.05e-18	82.0
k141_7278_15	SARG|gi|441475675|emb|CCQ25429.1|	31.5	143	464	211	6.57e-11	60.8
k141_7278_52	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	44.1	1043	1060	1024	0.0	939
k141_7278_52	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	44.1	1043	1060	1024	0.0	939
k141_7278_52	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	44.4	1055	1060	1033	0.0	932
k141_7278_52	SARG|gb|AEY83581|ARO:3000510|mupB	44.4	1055	1060	1033	0.0	932
k141_7278_52	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	43.8	1043	1060	1024	0.0	932
k141_7278_52	SARG|gb|CAA53189|ARO:3000521|mupA	43.8	1043	1060	1024	0.0	932
k141_7278_52	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	35.0	1126	1060	1107	1.23e-216	649
k141_7278_52	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	35.0	1126	1060	1107	1.23e-216	649
k141_7278_61	SARG|gb|WP_104671188.1|ARO:3003948|efrA	36.9	539	580	575	6.93e-110	339
k141_7278_61	SARG|gb|AAK76137.1|ARO:3000024|patA	32.9	562	580	564	8.23e-101	315
k141_7278_61	SARG|gi|695865802|ref|WP_032778631.1|	31.5	559	580	605	1.82e-66	226
k141_7278_61	SARG|gi|497748188|ref|WP_010062372.1|	31.3	559	580	605	2.52e-66	226
k141_7278_61	SARG|gi|764446018|ref|WP_044369325.1|	31.7	559	580	605	4.88e-66	225
k141_7278_61	SARG|gi|695887424|ref|WP_032788534.1|	31.5	559	580	605	6.79e-66	224
k141_7278_61	SARG|gi|827013130|ref|WP_047175495.1|	31.5	559	580	603	1.26e-65	224
k141_7278_61	SARG|gi|664180077|ref|WP_030714054.1|	31.5	559	580	605	1.31e-65	224
k141_7278_61	SARG|gi|951183771|ref|WP_057661487.1|	31.7	559	580	603	2.44e-65	223
k141_7278_61	SARG|gi|1045390184|ref|WP_065479071.1|	31.1	559	580	605	3.53e-65	223
k141_7278_62	SARG|gb|AAK76136.1|ARO:3000025|patB	32.6	611	639	588	6.75e-98	310
k141_7278_62	SARG|gb|AYV52072.1|ARO:3002882|lmrD	32.9	550	639	664	6.88e-90	291
k141_7278_62	SARG|gb|CDO61516.1|ARO:3003949|efrB	38.9	388	639	362	5.48e-78	251
k141_7278_62	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	29.1	621	639	579	6.31e-76	252
k141_7278_62	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	29.1	618	639	579	4.65e-75	250
k141_7278_62	SARG|gi|497748188|ref|WP_010062372.1|	31.3	530	639	605	1.16e-74	249
k141_7278_62	SARG|gi|695865802|ref|WP_032778631.1|	31.1	530	639	605	1.19e-73	247
k141_7278_62	SARG|gi|1045390184|ref|WP_065479071.1|	31.7	530	639	605	1.19e-73	247
k141_7278_62	SARG|gi|695887424|ref|WP_032788534.1|	31.1	530	639	605	3.21e-73	246
k141_7278_62	SARG|gi|663330365|ref|WP_030329892.1|	31.1	530	639	607	3.35e-73	246
k141_7278_69	SARG|gb|ADZ12699.1|ARO:3005091|RanA	33.2	244	252	258	2.48e-38	133
k141_7278_69	SARG|Q83LR7	38.1	226	252	648	3.93e-38	139
k141_7278_69	SARG|gi|647325472|ref|WP_025760953.1|	38.1	226	252	648	3.93e-38	139
k141_7278_69	SARG|gi|647323678|ref|WP_025760497.1|	38.1	226	252	648	3.93e-38	139
k141_7278_69	SARG|gi|446110305|ref|WP_000188160.1|	37.6	226	252	648	1.40e-37	138
k141_7278_69	SARG|gi|446110301|ref|WP_000188156.1|	37.6	226	252	648	2.63e-37	137
k141_7278_69	SARG|gi|898532714|ref|WP_049595067.1|	37.2	226	252	648	3.61e-37	137
k141_7278_69	SARG|gi|545167026|ref|WP_021521592.1|	37.2	226	252	648	6.79e-37	136
k141_7278_69	SARG|gi|919910427|ref|WP_052906132.1|	37.0	227	252	648	6.79e-37	136
k141_7278_69	SARG|gi|693106883|ref|WP_032260279.1|	37.2	226	252	648	9.31e-37	135
k141_7278_73	SARG|gb|ADZ12699.1|ARO:3005091|RanA	33.1	245	351	258	6.91e-35	127
k141_7278_73	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	32.7	220	351	255	3.54e-33	122
k141_7278_73	SARG|gi|895865878|ref|WP_048974758.1|	33.6	220	351	646	4.62e-26	108
k141_7278_83	SARG|gi|500448961|gb|EOP61695.1|	40.7	209	214	306	3.22e-46	154
k141_7278_83	SARG|gi|500465078|gb|EOP76697.1|	40.2	209	214	306	1.27e-45	152
k141_7278_83	SARG|gi|507044560|ref|WP_016115614.1|	41.1	202	214	306	1.79e-45	152
k141_7278_83	SARG|gi|445996719|ref|WP_000074574.1|	40.2	209	214	309	3.83e-45	151
k141_7278_83	SARG|gi|447195835|ref|WP_001273091.1|	39.7	209	214	306	5.01e-45	150
k141_7278_83	SARG|gi|445996710|ref|WP_000074565.1|	40.2	209	214	309	5.40e-45	150
k141_7278_83	SARG|gi|895808656|emb|COR83787.1|	40.2	209	214	309	5.40e-45	150
k141_7278_83	SARG|ZP_04081918	39.2	209	214	306	9.96e-45	150
k141_7278_83	SARG|gi|445996729|ref|WP_000074584.1|	40.2	209	214	309	1.07e-44	150
k141_7278_83	SARG|gi|895736250|emb|COF64653.1|	40.2	209	214	309	1.07e-44	150
k141_7278_100	CARD|gb|AAC16242.1|ARO:3005069|rsmA	45.3	53	75	61	9.20e-14	58.5
k141_118542_5	SARG|gb|MBW0764195.1|ARO:3007027|salC	55.6	36	74	541	1.35e-06	42.7
k141_183220_7	CARD|gb|WKR28567.1|ARO:3007678|IreK	33.5	627	748	718	8.92e-82	274
k141_183220_9	SARG|VXQ21601.1	34.1	337	355	344	2.18e-56	186
k141_183220_9	NCBI|WP_111690898.1|1|1|cfr(C)|cfr(C)|target_modification|2|CHLORAMPHENICOL/CLINDAMYCIN/FLORFENICOL/LINEZOLID/STREPTOGRAMIN/TIAMULIN|LINCOSAMIDE/OXAZOLIDINONE/PHENICOL/PLEUROMUTILIN/STREPTOGRAMIN|23S_rRNA_(adenine(2503)-C(8))-methyltransferase_Cfr(C)|AMR|multidrug	34.9	350	355	379	3.80e-56	186
k141_183220_9	megares|MEG_1680|Drugs|MLS|23S_rRNA_methyltransferases|CFR_1	34.9	350	355	416	6.60e-56	187
k141_183220_9	NCBI|WP_002349981.1|1|1|cfr(B)|cfr(B)|target_modification|2|CHLORAMPHENICOL/CLINDAMYCIN/LINEZOLID/RETAPAMULIN/STREPTOGRAMIN_B/VIRGINIAMYCIN|LINCOSAMIDE/OXAZOLIDINONE/PHENICOL/PLEUROMUTILIN/STREPTOGRAMIN|23S_rRNA_(adenine(2503)-C(8))-methyltransferase_Cfr(B)|AMR|multidrug	32.6	344	355	349	5.80e-54	180
k141_183220_9	SARG|gb|CDF47262.1|ARO:3004649|cfr(B)	32.6	344	355	349	5.80e-54	180
k141_183220_9	SARG|gb|AIX48090.1|ARO:3004599|clcD	32.8	344	355	349	1.61e-53	179
k141_214453_16	NCBI|WP_109545033.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	32.8	256	453	355	2.69e-29	116
k141_214453_16	megares|MEG_7602|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	32.8	256	453	355	2.69e-29	116
k141_214453_16	megares|MEG_7603|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	32.4	256	453	355	2.69e-29	116
k141_214453_16	SARG|BAE96115	32.4	256	453	355	2.69e-29	116
k141_214453_16	SARG|ACM47285	32.8	256	453	363	3.06e-29	116
k141_214453_16	NCBI|WP_063856854.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	31.6	256	453	356	3.41e-28	113
k141_214453_16	NCBI|WP_049898469.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	31.6	256	453	356	4.67e-28	113
k141_214453_16	NCBI|WP_063856862.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	31.6	256	453	356	8.77e-28	112
k141_214453_16	NCBI|WP_063856871.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	30.5	256	453	346	1.26e-26	108
k141_214453_16	megares|MEG_7604|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_2	33.0	197	453	209	2.41e-21	90.9
k141_214453_25	SARG|HE999704.1.gene3064.p01	27.4	179	453	241	7.59e-16	75.9
k141_214453_25	SARG|gi|441475675|emb|CCQ25429.1|	33.0	91	453	211	2.12e-10	59.3
k141_214453_26	SARG|gb|ANZ79476.1|ARO:3003908|Erm(47)	31.6	187	290	246	1.02e-22	93.2
k141_214453_26	SARG|L22689.1.gene1.p01	31.0	232	290	257	1.24e-21	90.5
k141_214453_26	SARG|ZP_04543635	31.7	189	290	266	1.75e-18	82.0
k141_214453_26	SARG|ZP_04055482	31.9	185	290	266	8.62e-18	80.1
k141_214453_26	SARG|AAA27431	31.9	185	290	266	8.62e-18	80.1
k141_214453_26	SARG|gi|7715978|gb|AAF68230.1|AF203972_3	31.9	185	290	266	8.62e-18	80.1
k141_214453_26	SARG|M14730.gene.p01	31.9	185	290	266	8.62e-18	80.1
k141_214453_26	megares|MEG_2833|Drugs|MLS|23S_rRNA_methyltransferases|ERMF_1	31.9	185	290	266	1.63e-17	79.3
k141_214453_26	SARG|CAC47934	31.4	185	290	266	2.24e-17	79.0
k141_214453_26	SARG|Q02607	31.4	185	290	266	2.24e-17	79.0
k141_214453_34	NCBI|WP_063856734.1|1|1|vanS-E|vanS-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-E|AMR|glycopeptide	27.6	370	690	357	4.77e-28	115
k141_214453_34	megares|MEG_7511|Drugs|Glycopeptide|VanE-type_regulator|VANSE_1	27.6	370	690	357	4.77e-28	115
k141_214453_34	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	28.8	274	690	380	9.34e-28	114
k141_214453_34	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	28.8	274	690	380	9.34e-28	114
k141_214453_34	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	28.4	289	690	365	1.81e-27	113
k141_214453_34	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	28.2	266	690	370	1.29e-25	108
k141_214453_34	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	26.2	305	690	367	1.81e-24	104
k141_214453_34	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	25.9	305	690	368	2.47e-24	104
k141_214453_34	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	27.5	291	690	381	2.35e-23	101
k141_214453_34	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	27.5	291	690	381	2.35e-23	101
k141_214453_35	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	45.5	233	242	231	5.06e-72	218
k141_214453_35	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	43.6	234	242	232	1.38e-69	212
k141_214453_35	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	43.5	232	242	232	2.77e-69	211
k141_214453_35	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	41.1	231	242	232	1.09e-63	197
k141_214453_35	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	40.3	231	242	229	5.64e-63	195
k141_214453_35	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	40.9	237	242	235	6.78e-63	195
k141_214453_35	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	41.8	237	242	233	2.56e-62	194
k141_214453_35	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	41.0	234	242	231	3.41e-62	193
k141_214453_35	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	41.3	230	242	231	6.84e-62	192
k141_214453_35	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	40.5	237	242	239	7.03e-61	190
k141_214594_2	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	36.4	217	218	220	2.06e-46	152
k141_214594_2	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.9	217	218	219	8.00e-46	150
k141_214594_2	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	34.8	227	218	230	1.54e-45	150
k141_214594_2	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.9	217	218	219	1.60e-45	149
k141_214594_2	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.9	217	218	220	1.64e-45	149
k141_214594_2	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.9	217	218	220	2.32e-45	149
k141_214594_2	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	36.1	230	218	233	2.37e-45	149
k141_214594_2	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	36.6	227	218	231	3.17e-45	149
k141_214594_2	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	34.5	226	218	229	2.38e-44	147
k141_214594_2	SARG|ZP_02848503	35.5	217	218	221	3.03e-43	144
k141_214594_20	SARG|P42332	34.9	212	284	306	9.80e-30	113
k141_214594_20	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	34.9	212	284	306	9.80e-30	113
k141_214594_20	SARG|gi|510143239|gb|AGN36970.1|	34.9	212	284	313	1.12e-29	113
k141_214594_20	SARG|gi|542061059|gb|ERI11611.1|	34.9	212	284	316	1.18e-29	113
k141_214594_20	SARG|ABB80128	34.4	212	284	306	5.15e-29	111
k141_214594_20	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	33.5	212	284	307	7.30e-29	110
k141_214594_20	SARG|gi|500448961|gb|EOP61695.1|	34.9	195	284	306	1.39e-28	110
k141_214594_20	SARG|gi|447195835|ref|WP_001273091.1|	34.4	212	284	306	1.39e-28	110
k141_214594_20	SARG|gi|445996709|ref|WP_000074564.1|	33.5	212	284	309	2.04e-28	109
k141_214594_20	SARG|gi|445996719|ref|WP_000074574.1|	34.0	212	284	309	2.84e-28	109
k141_214676_2	CARD|gb|AAA99503.1|ARO:3003250|bcrC	33.6	134	179	203	6.34e-15	68.6
k141_214676_2	SARG|gb|BAG33043.1|ARO:3003920|pgpB	28.5	165	179	236	1.36e-08	51.6
k141_214676_2	megares|MEG_5776|Drugs|Lipopeptide|Lipid_A_phosphatase|PGBB_1	28.5	165	179	236	1.36e-08	51.6
k141_214746_11	CARD|gb|BAD59497.1|ARO:3000501|rpoB2	54.0	1235	1283	1162	0.0	1200
k141_214746_11	CARD|gb|WP_041777404.1|ARO:3004480|Bado_rpoB_RIF	50.3	1297	1283	1186	0.0	1156
k141_214746_11	megares|MEG_8674|Drugs|Rifampin|Rifampin-resistant_beta-subunit_of_RNA_polymerase_RpoB|RPOB_1	50.3	1297	1283	1186	0.0	1156
k141_214746_19	SARG|L42544.gene.p01	28.4	677	708	651	2.30e-67	233
k141_214746_19	SARG|AAV80410	28.4	677	708	651	4.41e-67	232
k141_214746_19	SARG|YP_002850805	26.5	694	708	652	5.52e-64	223
k141_214746_19	SARG|NP_348076	26.3	687	708	652	1.05e-63	223
k141_214746_19	SARG|ZP_02952732	26.5	695	708	652	2.76e-63	221
k141_214746_19	SARG|ZP_02632674	26.5	695	708	660	3.18e-63	221
k141_214746_19	SARG|L20800.gene.p01	26.5	695	708	652	1.00e-62	220
k141_214746_19	megares|MEG_7175|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	27.0	679	708	639	8.65e-59	209
k141_214746_19	SARG|AJ514254.gene.p01	25.3	693	708	640	1.21e-58	208
k141_214746_19	SARG|gi|544707441|ref|WP_021137831.1|	26.3	677	708	639	2.09e-57	205
k141_214746_20	SARG|ACF08831	34.6	156	398	639	1.09e-16	80.9
k141_214746_20	NCBI|WP_050824634.1|1|1|tet(O)|tet(O)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(O)|AMR|tetracycline	36.8	133	398	639	6.17e-16	78.6
k141_214746_38	SARG|gi|943938624|ref|WP_055567802.1|	32.7	263	604	602	1.20e-39	152
k141_214746_38	SARG|gi|1045390184|ref|WP_065479071.1|	32.3	263	604	605	4.21e-39	150
k141_214746_38	SARG|gi|664170108|ref|WP_030704355.1|	33.1	263	604	603	1.03e-38	149
k141_214746_38	SARG|gi|695865802|ref|WP_032778631.1|	31.9	263	604	605	1.42e-38	149
k141_214746_38	SARG|gi|655401130|ref|WP_028800283.1|	31.6	263	604	599	1.82e-38	149
k141_214746_38	SARG|gi|501350226|ref|WP_012381861.1|	32.7	263	604	603	1.89e-38	149
k141_214746_38	SARG|gi|926376632|ref|WP_053705806.1|	32.3	263	604	620	2.21e-38	149
k141_214746_38	SARG|gi|490068471|ref|WP_003970646.1|	32.7	263	604	603	3.47e-38	148
k141_214746_38	SARG|gi|497748188|ref|WP_010062372.1|	31.9	263	604	605	3.54e-38	148
k141_214746_38	SARG|gi|799286378|ref|WP_045936958.1|	31.9	263	604	620	5.48e-38	147
k141_214746_39	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	31.1	267	590	574	4.77e-39	150
k141_214746_39	SARG|gb|AAC74000.1|ARO:3003950|msbA	31.0	261	590	582	3.14e-36	142
k141_214746_39	SARG|gb|WP_104671188.1|ARO:3003948|efrA	32.1	243	590	575	4.98e-34	135
k141_214746_39	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	29.4	299	590	578	2.82e-30	124
k141_214746_39	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	31.9	229	590	579	3.81e-30	124
k141_214746_39	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	31.1	228	590	579	5.34e-29	120
k141_214746_39	SARG|gb|AYV52072.1|ARO:3002882|lmrD	30.2	258	590	664	5.89e-28	117
k141_214746_39	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	28.7	247	590	255	2.45e-23	98.6
k141_214746_39	ResF|poxtA-Ef_1_WP094899500.1_1	28.0	246	590	538	1.71e-17	84.7
k141_214746_39	megares|MEG_8639|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|POXT_1	28.0	246	590	543	1.73e-17	84.7
k141_214746_40	SARG|gi|926351744|ref|WP_053683383.1|	26.2	554	592	648	7.28e-36	141
k141_214746_40	SARG|gb|WP_104671188.1|ARO:3003948|efrA	24.9	498	592	575	6.18e-35	138
k141_214746_40	SARG|gi|772774655|ref|WP_045322518.1|	25.9	552	592	620	5.29e-34	135
k141_214746_40	SARG|gi|917203192|ref|WP_051809904.1|	25.8	551	592	620	1.73e-33	134
k141_214746_40	SARG|gi|664556405|ref|WP_031071225.1|	25.6	550	592	602	6.79e-33	132
k141_214746_40	SARG|gi|799286378|ref|WP_045936958.1|	25.1	549	592	620	1.38e-32	131
k141_214746_40	SARG|gi|926294973|ref|WP_053631154.1|	25.1	549	592	620	1.38e-32	131
k141_214746_40	SARG|gi|926356413|ref|WP_053687351.1|	25.1	549	592	620	1.85e-32	131
k141_214746_40	SARG|gi|926345639|ref|WP_053677539.1|	25.1	549	592	620	1.85e-32	131
k141_214746_40	SARG|gi|917127754|ref|WP_051734466.1|	25.1	549	592	620	1.85e-32	131
k141_214746_44	CARD|gb|ATC67679.1|ARO:3000838|arlR	51.6	223	229	219	3.76e-73	220
k141_214746_44	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	38.8	232	229	232	1.85e-47	155
k141_214746_44	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	39.0	228	229	232	5.23e-47	154
k141_214746_44	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	39.4	231	229	231	4.05e-46	152
k141_214746_44	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	37.7	223	229	228	4.18e-45	149
k141_214746_44	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	39.5	223	229	232	4.67e-45	149
k141_214746_44	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	38.5	231	229	231	6.41e-45	149
k141_214746_44	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	38.1	231	229	231	1.81e-44	147
k141_214746_44	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	39.2	222	229	231	2.55e-44	147
k141_214746_44	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.8	226	229	219	2.89e-43	144
k141_214746_45	CARD|gb|ABD30512.1|ARO:3000839|arlS	35.7	249	386	451	3.54e-42	152
k141_214746_46	SARG|gb|APB03216.1|ARO:3003982|LlmA	60.8	286	288	287	2.07e-137	388
k141_214746_78	SARG|gi|498115003|ref|WP_010429159.1|	33.8	237	606	646	1.95e-29	122
k141_214746_78	SARG|gi|754493745|ref|WP_041910640.1|	33.8	237	606	646	2.60e-29	122
k141_214746_78	SARG|gi|782756348|ref|WP_045630015.1|	33.8	237	606	646	2.60e-29	122
k141_214746_78	SARG|gi|765031087|ref|WP_044596899.1|	33.8	237	606	646	6.18e-29	120
k141_214746_78	SARG|gi|896083144|ref|WP_049122651.1|	33.8	237	606	646	6.18e-29	120
k141_214746_78	SARG|gi|695748190|ref|WP_032674455.1|	33.8	237	606	646	8.24e-29	120
k141_214746_78	SARG|gi|544824889|ref|WP_021240890.1|	33.8	237	606	646	8.24e-29	120
k141_214746_78	SARG|gi|851931792|ref|WP_048222288.1|	33.8	237	606	646	8.24e-29	120
k141_214746_78	SARG|gi|836589868|ref|WP_047747112.1|	33.8	237	606	646	8.24e-29	120
k141_214746_78	SARG|gi|556301718|ref|WP_023292894.1|	33.8	237	606	646	8.24e-29	120
k141_247938_15	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	24.9	703	880	1024	1.76e-62	228
k141_247938_15	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	24.9	703	880	1024	1.76e-62	228
k141_247938_15	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	24.9	703	880	1024	5.81e-62	226
k141_247938_15	SARG|gb|CAA53189|ARO:3000521|mupA	24.9	703	880	1024	5.81e-62	226
k141_247938_15	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	24.9	634	880	1033	3.66e-61	224
k141_247938_15	SARG|gb|AEY83581|ARO:3000510|mupB	24.9	634	880	1033	3.66e-61	224
k141_247938_22	SARG|gb|AAC74000.1|ARO:3003950|msbA	28.0	478	646	582	1.07e-48	178
k141_247938_22	SARG|gi|917155568|ref|WP_051762280.1|	32.1	343	646	620	3.44e-48	177
k141_247938_22	SARG|gi|860594225|ref|WP_048475168.1|	31.5	343	646	620	3.44e-48	177
k141_247938_22	SARG|gi|917166849|ref|WP_051773561.1|	31.8	343	646	620	1.20e-47	176
k141_247938_22	SARG|gi|926294973|ref|WP_053631154.1|	31.5	343	646	620	2.24e-47	175
k141_247938_22	SARG|gi|926356413|ref|WP_053687351.1|	31.5	343	646	620	3.06e-47	175
k141_247938_22	SARG|gi|664556405|ref|WP_031071225.1|	29.0	449	646	602	6.14e-47	174
k141_247938_22	SARG|gi|917229923|ref|WP_051836635.1|	31.2	343	646	620	7.80e-47	174
k141_247938_22	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	26.9	594	646	579	8.31e-47	173
k141_247938_22	SARG|gi|926400371|ref|WP_053728483.1|	28.9	456	646	603	8.51e-47	173
k141_247938_23	SARG|gb|AYV52072.1|ARO:3002882|lmrD	32.7	490	599	664	1.28e-82	271
k141_247938_23	SARG|gb|AAK76136.1|ARO:3000025|patB	32.2	509	599	588	3.93e-78	257
k141_247938_23	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	30.6	588	599	579	4.46e-78	257
k141_247938_23	SARG|gi|944152509|ref|WP_055644808.1|	32.9	513	599	616	3.95e-77	255
k141_247938_23	SARG|gi|948137056|ref|WP_056795395.1|	32.6	513	599	602	5.63e-77	254
k141_247938_23	SARG|gi|928900436|ref|WP_053931243.1|	32.9	513	599	600	7.78e-76	251
k141_247938_23	SARG|gi|664579989|ref|WP_031094015.1|	32.9	513	599	601	7.95e-76	251
k141_247938_23	SARG|gi|944009777|ref|WP_055601444.1|	32.4	515	599	628	2.00e-75	251
k141_247938_23	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	30.5	586	599	579	5.01e-75	249
k141_247938_23	SARG|gi|860594225|ref|WP_048475168.1|	33.2	509	599	620	1.24e-74	249
k141_72898_27	SARG|gb|ABA71733.1|ARO:3002972|vanTG	35.0	369	401	712	2.01e-72	239
k141_72898_27	NCBI|CZR78671.1|1|1|vanT-Cd|vanT-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-Cd|AMR|glycopeptide	36.3	369	401	712	2.25e-67	225
k141_72898_27	NCBI|WP_063856752.1|1|1|vanT-G|vanT-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-G|AMR|glycopeptide	31.4	369	401	711	1.51e-56	196
k141_72898_27	SARG|AAY67970	31.2	369	401	698	2.82e-51	181
k141_72898_27	SARG|AF162694.1.gene4.p01	30.9	369	401	698	1.02e-50	180
k141_72898_27	SARG|gi|657686198|ref|WP_029487032.1|	30.9	369	401	698	1.02e-50	180
k141_72898_27	SARG|JF802084.2.gene3.p01	31.7	366	401	700	2.57e-49	176
k141_72898_27	NCBI|WP_063856756.1|1|1|vanT-C|vanT-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-C|AMR|glycopeptide	32.7	370	401	700	1.10e-46	169
k141_72898_27	NCBI|WP_063856755.1|1|1|vanT-C|vanT-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-C|AMR|glycopeptide	33.0	358	401	700	5.37e-46	167
k141_72898_27	NCBI|WP_063856759.1|1|1|vanTc3|vanTc3|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT|AMR|glycopeptide	31.7	369	401	700	6.81e-42	155
k141_40193_4	SARG|gb|AAC74000.1|ARO:3003950|msbA	24.5	546	561	582	1.06e-37	145
k141_40193_4	SARG|gb|AAK76136.1|ARO:3000025|patB	26.0	520	561	588	2.61e-28	118
k141_40193_4	SARG|gb|AYV52072.1|ARO:3002882|lmrD	25.4	492	561	664	4.73e-26	111
k141_40193_4	NCBI|WP_000420313.1|1|1|msr(D)|msr(D)|target_protection|2|AZITHROMYCIN/ERYTHROMYCIN/STREPTOGRAMIN_B|MACROLIDE/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_Msr(D)|AMR|multidrug	27.0	200	561	487	2.33e-07	52.4
k141_40193_4	NCBI|WP_000420317.1|1|1|msr(D)|msr(D)|target_protection|2|AZITHROMYCIN/ERYTHROMYCIN/STREPTOGRAMIN_B|MACROLIDE/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_Msr(D)|AMR|multidrug	27.1	199	561	487	9.35e-07	50.4
k141_40193_16	SARG|AUI09862.1	46.5	271	276	287	1.29e-81	246
k141_40193_16	SARG|AJ459418.gene.p01	35.1	262	276	263	5.39e-46	154
k141_40193_16	SARG|gi|970263436|ref|WP_058647620.1|	35.1	262	276	263	7.59e-46	154
k141_40193_16	SARG|gi|691356724|ref|WP_032072921.1|	31.7	262	276	279	6.72e-36	128
k141_40193_16	SARG|gi|446181163|ref|WP_000259018.1|	31.7	262	276	279	9.43e-36	128
k141_40193_16	SARG|gi|394786240|gb|AFN40206.1|	31.7	262	276	308	1.28e-35	128
k141_40193_16	SARG|gi|499772318|ref|WP_011453052.1|	31.3	246	276	272	9.10e-34	122
k141_40193_16	SARG|gi|553729091|ref|WP_023063817.1|	31.0	245	276	271	4.80e-33	120
k141_40193_16	NCBI|WP_001043265.1|1|1|sul2|sul2|insensitivity|2|sulfonamide|sulfonamide|sulfonamide-resistant_dihydropteroate_synthase_Sul2|AMR|sulfonamide	31.0	245	276	271	4.80e-33	120
k141_40193_16	SARG|gi|486033774|ref|WP_001505252.1|	31.0	245	276	271	9.42e-33	120
k141_216156_13	NCBI|WP_002368696.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	30.4	299	498	447	2.86e-35	135
k141_216156_13	NCBI|WP_002382867.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	29.8	299	498	447	1.25e-33	131
k141_216156_13	NCBI|WP_012579101.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	29.8	299	498	447	1.25e-33	131
k141_216156_13	NCBI|WP_063856739.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	29.8	299	498	447	1.25e-33	131
k141_216156_13	NCBI|WP_063856751.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	29.1	299	498	454	1.47e-31	125
k141_216156_13	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	22.9	301	498	392	2.83e-20	91.7
k141_216156_13	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	22.6	243	498	364	5.22e-20	90.5
k141_216156_13	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	22.6	243	498	364	5.22e-20	90.5
k141_216156_13	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	23.3	309	498	359	5.34e-19	87.4
k141_216156_13	CARD|gb|ADM92606.1|ARO:3000549|adeS	24.1	295	498	361	2.74e-15	76.3
k141_216156_14	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	40.0	220	228	220	1.10e-51	166
k141_216156_14	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	40.0	220	228	219	1.51e-51	165
k141_216156_14	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	39.1	230	228	231	1.52e-51	166
k141_216156_14	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	40.0	220	228	220	1.56e-51	165
k141_216156_14	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	40.0	220	228	220	2.20e-51	165
k141_216156_14	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	39.5	220	228	219	1.21e-50	163
k141_216156_14	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	41.0	229	228	231	6.87e-50	161
k141_216156_14	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	41.0	229	228	231	6.87e-50	161
k141_216156_14	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	37.7	228	228	232	9.99e-50	161
k141_216156_14	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	37.7	228	228	232	9.99e-50	161
k141_24174_4	SARG|gb|AAC74000.1|ARO:3003950|msbA	31.4	506	586	582	5.00e-84	272
k141_24174_4	SARG|gi|639148059|ref|WP_024490169.1|	29.5	560	586	602	1.12e-76	253
k141_24174_4	SARG|gi|664395661|ref|WP_030922045.1|	29.8	560	586	601	2.13e-76	253
k141_24174_4	SARG|gi|948137056|ref|WP_056795395.1|	29.5	560	586	602	3.04e-76	252
k141_24174_4	SARG|gi|493394434|ref|WP_006350564.1|	29.3	553	586	602	4.25e-76	252
k141_24174_4	SARG|gi|496018010|ref|WP_008742581.1|	30.3	544	586	623	6.74e-76	252
k141_24174_4	SARG|gi|739906046|ref|WP_037756452.1|	29.5	560	586	620	8.81e-76	251
k141_24174_4	SARG|gi|648667297|ref|WP_026359044.1|	29.2	555	586	605	8.86e-76	251
k141_24174_4	SARG|gi|516574297|ref|WP_017949361.1|	29.5	560	586	620	1.23e-75	251
k141_24174_4	SARG|gi|1045390184|ref|WP_065479071.1|	29.3	556	586	605	1.24e-75	251
k141_24174_5	SARG|AF170880.4.gene1.p01	34.6	586	609	615	1.93e-95	304
k141_24174_5	SARG|gi|558888514|ref|WP_023543283.1|	34.8	586	609	615	3.80e-95	303
k141_24174_5	SARG|gi|928900436|ref|WP_053931243.1|	34.6	586	609	600	1.41e-94	301
k141_24174_5	SARG|gi|664579989|ref|WP_031094015.1|	34.6	586	609	601	1.45e-94	301
k141_24174_5	SARG|gi|695842130|ref|WP_032755430.1|	34.5	579	609	603	3.00e-94	300
k141_24174_5	SARG|gi|505420018|ref|WP_015607120.1|	34.5	579	609	603	3.00e-94	300
k141_24174_5	SARG|gi|926400371|ref|WP_053728483.1|	33.9	584	609	603	3.00e-94	300
k141_24174_5	SARG|gi|1045390184|ref|WP_065479071.1|	34.4	587	609	605	4.43e-94	300
k141_24174_5	SARG|gi|948137056|ref|WP_056795395.1|	34.5	586	609	602	5.75e-94	300
k141_24174_5	SARG|gi|664395661|ref|WP_030922045.1|	34.5	586	609	601	7.87e-94	299
k141_24174_7	NCBI|WP_005480402.1|1|1|tet(35)|tet(35)|efflux|2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_Na+/H+_antiporter_family_transporter_Tet(35)|AMR|tetracycline	41.0	507	555	533	6.22e-112	342
k141_24174_7	SARG|AF353562.gene.p01	38.7	346	555	369	2.62e-62	208
k141_24174_19	CARD|gb|AAC75429.1|ARO:3000833|evgS	30.1	382	413	1197	3.31e-45	166
k141_24174_25	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	23.8	856	810	1024	4.40e-35	142
k141_24174_25	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	23.8	856	810	1024	4.40e-35	142
k141_24174_25	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	23.8	856	810	1024	4.40e-35	142
k141_24174_25	SARG|gb|CAA53189|ARO:3000521|mupA	23.8	856	810	1024	4.40e-35	142
k141_24174_25	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	23.7	676	810	1033	7.09e-30	126
k141_24174_25	SARG|gb|AEY83581|ARO:3000510|mupB	23.7	676	810	1033	7.09e-30	126
k141_24174_25	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	21.7	914	810	1107	1.55e-17	86.7
k141_24174_25	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	21.7	914	810	1107	1.55e-17	86.7
k141_248936_7	SARG|gi|445996719|ref|WP_000074574.1|	30.2	215	764	309	1.85e-22	97.8
k141_248936_7	SARG|gi|445996710|ref|WP_000074565.1|	30.2	215	764	309	1.85e-22	97.8
k141_248936_7	SARG|gi|507044560|ref|WP_016115614.1|	31.6	196	764	306	2.37e-22	97.4
k141_248936_7	SARG|gi|507035724|ref|WP_016107411.1|	30.2	199	764	309	4.55e-22	96.7
k141_248936_7	SARG|gi|895736250|emb|COF64653.1|	30.2	215	764	309	4.55e-22	96.7
k141_248936_7	SARG|gi|446110087|ref|WP_000187942.1|	30.2	215	764	309	4.55e-22	96.7
k141_248936_7	SARG|gi|445996698|ref|WP_000074553.1|	30.2	199	764	309	4.55e-22	96.7
k141_248936_7	SARG|gi|445996697|ref|WP_000074552.1|	30.2	199	764	309	4.55e-22	96.7
k141_248936_7	SARG|gi|445996714|ref|WP_000074569.1|	30.2	215	764	309	4.55e-22	96.7
k141_248936_7	SARG|gi|446026113|ref|WP_000103968.1|	32.0	194	764	306	5.84e-22	96.3
k141_248936_8	CARD|gb|WKR28567.1|ARO:3007678|IreK	29.4	272	704	718	1.26e-18	89.4
k141_41332_11	SARG|L42544.gene.p01	31.5	632	860	651	1.24e-93	307
k141_41332_11	SARG|AAV80410	31.5	632	860	651	2.40e-93	306
k141_41332_11	SARG|YP_002850805	32.5	631	860	652	2.58e-90	298
k141_41332_11	SARG|ZP_02952732	32.5	627	860	652	6.94e-90	297
k141_41332_11	SARG|ZP_02632674	32.5	627	860	660	8.40e-90	297
k141_41332_11	SARG|L20800.gene.p01	32.5	627	860	652	1.87e-89	296
k141_41332_11	SARG|NP_348076	31.0	639	860	652	3.66e-85	284
k141_41332_11	NCBI|WP_063856409.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	30.1	622	860	641	2.03e-84	282
k141_41332_11	SARG|AAZ79478	30.1	622	860	657	2.94e-84	282
k141_41332_11	NCBI|WP_063856408.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	29.9	622	860	654	1.40e-82	277
k141_41332_14	SARG|gi|948137056|ref|WP_056795395.1|	29.5	491	612	602	5.56e-57	201
k141_41332_14	SARG|gi|1045390184|ref|WP_065479071.1|	29.1	491	612	605	8.08e-57	201
k141_41332_14	SARG|gb|AAC74000.1|ARO:3003950|msbA	28.2	472	612	582	1.97e-56	199
k141_41332_14	SARG|gi|764446018|ref|WP_044369325.1|	29.1	491	612	605	7.73e-56	198
k141_41332_14	SARG|gi|695865802|ref|WP_032778631.1|	28.9	491	612	605	2.03e-55	197
k141_41332_14	SARG|gi|664180077|ref|WP_030714054.1|	28.9	491	612	605	5.33e-55	196
k141_41332_14	SARG|gi|695887424|ref|WP_032788534.1|	28.9	491	612	605	7.35e-55	195
k141_41332_14	SARG|gi|951183771|ref|WP_057661487.1|	28.5	491	612	603	1.35e-54	194
k141_41332_14	SARG|gi|497748188|ref|WP_010062372.1|	28.7	491	612	605	5.04e-54	193
k141_41332_14	SARG|gi|799286378|ref|WP_045936958.1|	29.1	491	612	620	1.67e-53	192
k141_41332_15	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	32.8	583	591	579	5.29e-84	272
k141_41332_15	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	32.9	598	591	579	2.03e-83	271
k141_41332_15	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	30.2	586	591	578	2.33e-80	263
k141_41332_15	SARG|gi|1011969930|ref|WP_062776015.1|	30.3	581	591	601	7.82e-80	262
k141_41332_15	SARG|AF170880.4.gene1.p01	30.0	580	591	615	1.12e-78	259
k141_41332_15	SARG|gi|493394434|ref|WP_006350564.1|	29.7	580	591	602	1.63e-78	258
k141_41332_15	SARG|gi|648667297|ref|WP_026359044.1|	30.0	580	591	605	2.44e-78	258
k141_41332_15	SARG|gi|944470764|ref|WP_055701183.1|	30.6	581	591	601	3.12e-78	258
k141_41332_15	SARG|gi|558888514|ref|WP_023543283.1|	29.8	580	591	615	4.27e-78	258
k141_41332_15	SARG|gi|505420018|ref|WP_015607120.1|	29.7	580	591	603	4.56e-78	257
k141_121276_24	CARD|gb|AAC75429.1|ARO:3000833|evgS	31.7	366	838	1197	1.16e-40	160
k141_121276_24	CARD|gb|CYF42523.1|ARO:3004047|kdpD	25.7	226	838	885	2.65e-15	79.3
k141_121276_24	CARD|gb|ATC67679.1|ARO:3000838|arlR	29.2	120	838	219	4.65e-08	53.5
k141_121276_26	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	28.7	143	645	231	9.21e-12	64.3
k141_121276_26	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	29.8	104	645	231	2.48e-10	60.1
k141_121276_26	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	30.1	133	645	231	3.34e-10	59.7
k141_121276_26	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	32.4	105	645	232	8.29e-10	58.5
k141_121276_26	CARD|gb|AAD51348.1|ARO:3003066|smeR	37.3	75	645	229	5.13e-08	53.1
k141_121276_26	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	26.9	119	645	252	9.23e-06	46.6
k141_121276_53	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	34.3	251	246	255	1.67e-43	146
k141_121276_53	SARG|gb|ADZ12699.1|ARO:3005091|RanA	33.6	238	246	258	5.07e-43	145
k141_121276_53	SARG|gi|495736522|ref|WP_008461101.1|	38.1	226	246	648	8.19e-42	149
k141_121276_53	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	27.9	208	246	578	2.52e-17	79.7
k141_217014_9	SARG|gb|AAK76136.1|ARO:3000025|patB	35.3	535	728	588	9.41e-102	323
k141_217014_9	SARG|gb|AYV52072.1|ARO:3002882|lmrD	36.0	520	728	664	5.37e-92	300
k141_217014_9	SARG|gb|CDO61516.1|ARO:3003949|efrB	43.2	352	728	362	1.87e-83	268
k141_217014_9	SARG|AF170880.4.gene1.p01	33.2	509	728	615	4.67e-79	264
k141_217014_9	SARG|gi|558888514|ref|WP_023543283.1|	33.2	509	728	615	6.51e-79	263
k141_217014_9	SARG|gi|947982677|ref|WP_056642336.1|	34.2	512	728	626	1.62e-78	263
k141_217014_9	SARG|gi|639892676|ref|WP_024755698.1|	34.2	512	728	631	1.81e-78	263
k141_217014_9	SARG|gi|648667297|ref|WP_026359044.1|	32.6	503	728	605	5.24e-78	261
k141_217014_9	SARG|gi|505420018|ref|WP_015607120.1|	32.7	511	728	603	6.97e-78	260
k141_217014_9	SARG|gi|662129758|ref|WP_030081404.1|	32.6	503	728	605	1.02e-77	260
k141_217014_10	SARG|gb|WP_104671188.1|ARO:3003948|efrA	43.9	510	586	575	3.15e-123	374
k141_217014_10	SARG|gb|AAK76137.1|ARO:3000024|patA	34.8	512	586	564	1.65e-89	286
k141_217014_10	SARG|gb|AAC74000.1|ARO:3003950|msbA	29.7	498	586	582	3.49e-60	209
k141_217014_10	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	31.1	499	586	579	4.32e-57	200
k141_217014_10	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	31.3	498	586	579	2.12e-55	196
k141_217014_10	SARG|gi|1045390184|ref|WP_065479071.1|	40.4	255	586	605	1.20e-54	194
k141_217014_10	SARG|gi|748767925|ref|WP_040019608.1|	32.4	373	586	623	1.60e-54	194
k141_217014_10	SARG|gi|501350226|ref|WP_012381861.1|	40.8	255	586	603	1.60e-54	194
k141_217014_10	SARG|gi|695865802|ref|WP_032778631.1|	40.4	255	586	605	1.66e-54	194
k141_217014_10	SARG|gi|664170108|ref|WP_030704355.1|	40.8	255	586	603	3.06e-54	193
k141_58143_23	megares|MEG_5400|Drugs|beta-lactam|Penicillin_binding_protein|PBP2_1	26.2	385	959	633	2.92e-24	107
k141_58143_23	SARG|gb|AQX82857.1|ARO:3004185|mecD	32.3	133	959	678	1.26e-08	57.8
k141_217368_17	SARG|gb|APB03219.1|ARO:3003986|TaeA	49.2	652	608	648	3.61e-198	569
k141_217368_17	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.3	563	608	655	4.36e-64	221
k141_217368_17	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.3	563	608	655	4.36e-64	221
k141_217368_17	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.3	563	608	655	6.04e-64	221
k141_217368_17	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.3	563	608	655	1.60e-63	220
k141_217368_17	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.3	563	608	655	1.60e-63	220
k141_217368_17	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.1	563	608	655	5.90e-63	218
k141_217368_17	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.1	563	608	655	5.90e-63	218
k141_217368_17	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.1	563	608	655	5.90e-63	218
k141_217368_17	megares|MEG_4311|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.1	563	608	655	5.90e-63	218
k141_217368_31	NCBI|XSG12258.1|1|1|drcS|drcS||1|||daptomycin_efflux_sensor_histidine_kinase_DrcS|AMR|peptide	23.8	223	890	341	1.06e-10	63.2
k141_217368_32	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	34.5	119	303	252	1.20e-14	71.2
k141_250629_3	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	45.2	679	645	703	3.17e-171	504
k141_25547_16	SARG|gi|500448961|gb|EOP61695.1|	38.5	208	216	306	1.81e-42	144
k141_25547_16	SARG|gi|500465078|gb|EOP76697.1|	38.5	208	216	306	1.81e-42	144
k141_25547_16	SARG|ZP_04081918	38.0	208	216	306	3.60e-42	143
k141_25547_16	SARG|gi|447195835|ref|WP_001273091.1|	37.5	208	216	306	5.06e-42	143
k141_25547_16	SARG|gi|447195836|ref|WP_001273092.1|	37.0	208	216	306	1.41e-41	142
k141_25547_16	SARG|gi|500194536|ref|WP_011867743.1|	37.5	208	216	306	2.80e-41	141
k141_25547_16	SARG|gi|445996710|ref|WP_000074565.1|	38.6	210	216	309	1.18e-40	139
k141_25547_16	SARG|gi|488120365|ref|WP_002191762.1|	38.1	210	216	309	2.33e-40	139
k141_25547_16	SARG|gi|507044560|ref|WP_016115614.1|	37.6	202	216	306	3.06e-40	138
k141_25547_16	SARG|gi|895736250|emb|COF64653.1|	38.1	210	216	309	4.60e-40	138
k141_25547_26	SARG|AY082011.1.gene6.p01	27.8	216	388	323	6.14e-11	62.0
k141_25547_26	SARG|gi|552942232|ref|WP_023043160.1|	27.8	216	388	323	1.10e-10	61.2
k141_234357_27	SARG|gi|1001720867|ref|WP_061274204.1|	42.7	218	233	648	7.04e-55	184
k141_234357_27	SARG|gi|495736522|ref|WP_008461101.1|	42.2	218	233	648	1.36e-54	184
k141_234357_27	SARG|gi|746253210|ref|WP_039301529.1|	42.2	218	233	648	1.36e-54	184
k141_234357_27	SARG|Q83LR7	42.2	218	233	648	5.10e-54	182
k141_234357_27	SARG|gi|647325472|ref|WP_025760953.1|	42.2	218	233	648	5.10e-54	182
k141_234357_27	SARG|gi|647323678|ref|WP_025760497.1|	42.2	218	233	648	5.10e-54	182
k141_234357_27	SARG|gi|1035670474|ref|WP_064517458.1|	41.5	224	233	648	1.37e-53	181
k141_234357_27	SARG|gi|1035706844|ref|WP_064548272.1|	39.7	234	233	648	1.37e-53	181
k141_234357_27	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	40.1	237	233	255	1.41e-53	172
k141_234357_27	SARG|gi|1035717981|ref|WP_064557480.1|	42.2	218	233	648	1.91e-53	181
k141_59382_1	SARG|gi|740610794|ref|WP_038396317.1|	39.5	238	764	648	6.10e-34	137
k141_59382_1	SARG|gb|AAC74000.1|ARO:3003950|msbA	31.1	209	764	582	4.54e-18	87.4
k141_59382_1	NCBI|AJP12342.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	26.8	257	764	550	2.26e-10	62.8
k141_59382_1	NCBI|AKC61310.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	26.0	219	764	552	6.85e-10	61.2
k141_59382_2	SARG|GQ205627.2.gene1.p01	27.0	248	892	525	2.68e-07	53.1
k141_59382_3	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	31.5	222	784	255	2.57e-30	119
k141_59382_3	SARG|gb|AAC74000.1|ARO:3003950|msbA	31.1	206	784	582	4.75e-18	87.4
k141_59382_3	NCBI|AJP12342.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	25.7	222	784	550	2.82e-09	59.3
k141_59382_3	NCBI|AKC61310.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	27.4	219	784	552	1.12e-08	57.4
k141_59382_3	SARG|gb|CDO61516.1|ARO:3003949|efrB	23.7	186	784	362	9.18e-08	53.9
k141_59382_4	SARG|GQ205627.2.gene1.p01	25.7	206	898	525	6.17e-07	52.0
k141_202964_7	SARG|gi|447195835|ref|WP_001273091.1|	35.7	311	317	306	3.23e-51	170
k141_202964_7	SARG|ZP_04081918	35.4	311	317	306	4.55e-51	170
k141_202964_7	SARG|gi|447195836|ref|WP_001273092.1|	35.4	311	317	306	9.01e-51	169
k141_202964_7	SARG|gi|542061059|gb|ERI11611.1|	36.0	311	317	316	6.45e-50	167
k141_202964_7	SARG|gi|507055561|ref|WP_016126482.1|	32.8	311	317	309	5.87e-49	164
k141_202964_7	SARG|P42332	34.7	311	317	306	2.13e-48	163
k141_202964_7	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	34.7	311	317	306	2.13e-48	163
k141_202964_7	SARG|gi|510143239|gb|AGN36970.1|	34.7	311	317	313	2.54e-48	163
k141_202964_7	SARG|ABB80128	34.7	311	317	306	2.99e-48	162
k141_202964_7	SARG|AAD21213	34.4	311	317	306	2.99e-48	162
k141_11876_25	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	44.1	227	232	233	9.02e-63	194
k141_11876_25	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	42.4	224	232	231	1.10e-60	189
k141_11876_25	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	43.1	225	232	232	2.28e-60	188
k141_11876_25	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	41.7	230	232	239	5.66e-60	187
k141_11876_25	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	44.1	229	232	232	1.30e-59	186
k141_11876_25	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	44.1	229	232	232	1.30e-59	186
k141_11876_25	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	41.8	225	232	231	1.01e-58	184
k141_11876_25	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	43.2	227	232	232	1.04e-58	184
k141_11876_25	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	40.5	227	232	231	1.43e-58	184
k141_11876_25	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	40.5	227	232	231	1.43e-58	184
k141_11876_26	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	30.7	244	495	381	6.67e-32	125
k141_11876_26	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	30.7	244	495	381	6.67e-32	125
k141_11876_26	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	31.7	240	495	381	2.35e-31	123
k141_11876_26	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	31.7	240	495	381	2.35e-31	123
k141_11876_26	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	29.9	244	495	381	6.04e-31	122
k141_11876_26	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	29.9	244	495	381	6.04e-31	122
k141_11876_26	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	30.5	259	495	392	7.19e-31	122
k141_11876_26	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	33.5	221	495	380	1.52e-30	121
k141_11876_26	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	33.5	221	495	380	1.52e-30	121
k141_11876_26	NCBI|WP_002305818.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	31.9	213	495	384	4.42e-28	114
k141_11876_42	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	26.0	223	241	343	5.85e-15	72.0
k141_11876_42	SARG|gi|953808775|ref|WP_058042812.1|	24.2	236	241	608	1.45e-13	68.6
k141_11876_42	SARG|gi|517204321|ref|WP_018393139.1|	27.1	177	241	492	1.39e-09	56.6
k141_11876_42	SARG|AXF35727.1	24.6	211	241	497	1.87e-09	56.2
k141_11876_42	SARG|gi|817536927|ref|WP_046586836.1|	29.6	162	241	492	2.51e-09	55.8
k141_11876_42	SARG|gi|738121094|ref|WP_036079133.1|	26.6	177	241	493	2.51e-09	55.8
k141_11876_42	SARG|AJ579365.gene.p01	26.6	177	241	492	3.37e-09	55.5
k141_11876_42	SARG|gi|951389844|ref|WP_057765492.1|	30.2	162	241	492	6.10e-09	54.7
k141_11876_42	SARG|gi|727118387|ref|WP_033626720.1|	27.7	195	241	498	1.11e-08	53.9
k141_11876_42	SARG|gi|488349878|ref|WP_002419263.1|	27.7	195	241	498	1.11e-08	53.9
k141_60088_19	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	29.5	312	312	307	4.06e-37	133
k141_60088_19	SARG|gi|542061059|gb|ERI11611.1|	28.5	309	312	316	4.33e-29	112
k141_60088_19	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	28.5	305	312	293	5.42e-29	111
k141_60088_19	SARG|gi|488068784|ref|WP_002140181.1|	27.7	311	312	309	1.97e-28	110
k141_60088_19	SARG|gi|447057510|ref|WP_001134766.1|	27.7	311	312	309	1.97e-28	110
k141_60088_19	SARG|gi|488130770|ref|WP_002201978.1|	27.7	311	312	309	2.74e-28	110
k141_60088_19	SARG|gi|507023808|ref|WP_016095885.1|	27.7	311	312	309	3.81e-28	109
k141_60088_19	SARG|gi|488053456|ref|WP_002124853.1|	27.3	311	312	309	5.29e-28	109
k141_60088_19	SARG|P42332	28.2	309	312	306	6.96e-28	108
k141_60088_19	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	28.2	309	312	306	6.96e-28	108
k141_60088_26	CARD|gb|AEX49906.1|ARO:3003583|basS	31.4	236	246	477	1.06e-20	89.4
k141_60088_27	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	43.3	224	229	228	1.13e-61	191
k141_60088_27	CARD|gb|ATC67679.1|ARO:3000838|arlR	42.2	225	229	219	5.55e-60	187
k141_60088_27	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	46.1	230	229	233	1.21e-59	186
k141_60088_27	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	41.3	230	229	231	1.29e-58	184
k141_60088_27	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	41.3	230	229	231	1.83e-58	183
k141_60088_27	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	41.3	230	229	231	2.59e-58	183
k141_60088_27	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	40.5	227	229	232	1.07e-57	181
k141_60088_27	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	44.8	232	229	235	2.35e-57	181
k141_60088_27	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	40.9	230	229	231	2.95e-57	180
k141_60088_27	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	40.4	228	229	232	4.30e-57	180
k141_219177_6	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	38.0	229	223	231	5.86e-41	138
k141_219177_6	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	38.0	229	223	231	5.86e-41	138
k141_219177_6	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	36.2	229	223	231	4.62e-40	136
k141_219177_6	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	36.5	230	223	232	6.70e-40	135
k141_219177_6	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	36.5	230	223	232	6.70e-40	135
k141_219177_6	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	36.7	229	223	231	9.20e-40	135
k141_219177_6	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	37.1	229	223	231	9.20e-40	135
k141_219177_6	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	34.5	226	223	232	7.44e-39	133
k141_219177_6	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	34.6	231	223	233	1.68e-37	129
k141_219177_6	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	34.5	229	223	231	3.17e-37	129
k141_93094_16	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	27.5	211	459	307	3.89e-13	68.9
k141_93094_23	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	24.9	281	485	370	1.13e-27	112
k141_93094_23	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	22.9	280	485	365	1.26e-24	103
k141_93094_23	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	23.8	281	485	381	2.85e-24	103
k141_93094_23	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	23.8	281	485	381	2.85e-24	103
k141_93094_23	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	25.9	239	485	381	1.30e-23	101
k141_93094_23	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	25.9	239	485	381	1.30e-23	101
k141_93094_23	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	25.5	239	485	381	2.38e-23	100
k141_93094_23	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	25.5	239	485	381	2.38e-23	100
k141_93094_23	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	23.5	264	485	381	1.46e-22	98.2
k141_93094_23	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	23.5	264	485	381	1.46e-22	98.2
k141_93094_30	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	34.5	206	222	232	7.08e-32	115
k141_93094_30	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.8	201	222	219	1.02e-31	114
k141_93094_30	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	35.3	207	222	231	1.37e-31	114
k141_93094_30	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.8	201	222	219	1.44e-31	114
k141_93094_30	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.8	201	222	220	1.47e-31	114
k141_93094_30	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.8	201	222	220	2.91e-31	113
k141_93094_30	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.8	201	222	220	5.77e-31	112
k141_93094_30	CARD|gb|SIP52035.1|ARO:3004054|Paer_CpxR	36.8	204	222	225	9.16e-31	112
k141_93094_30	CARD|gb|AAG06465.1|ARO:3005063|cprR	30.1	219	222	223	1.44e-28	106
k141_93094_30	NCBI|WP_063856729.1|1|1|vanR-O|vanR-O|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-O|AMR|glycopeptide	33.3	201	222	233	7.51e-27	102
k141_93094_31	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	24.6	224	418	381	4.77e-20	90.1
k141_93094_31	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	24.6	224	418	381	4.77e-20	90.1
k141_93094_31	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	25.0	224	418	381	6.45e-20	89.7
k141_93094_31	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	25.0	224	418	381	6.45e-20	89.7
k141_93094_31	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	25.0	224	418	381	6.45e-20	89.7
k141_93094_31	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	25.0	224	418	381	6.45e-20	89.7
k141_93094_31	megares|MEG_7507|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	25.3	221	418	381	1.59e-19	88.6
k141_93094_31	NCBI|WP_063856738.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	25.3	221	418	381	1.59e-19	88.6
k141_93094_31	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	25.0	224	418	381	7.11e-19	86.7
k141_93094_31	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	25.0	224	418	381	7.11e-19	86.7
k141_93094_43	SARG|ZP_04528247	61.3	284	285	279	8.30e-113	325
k141_93094_43	SARG|YP_002929946	61.8	283	285	282	2.62e-112	324
k141_93094_43	SARG|ZP_03958019	56.5	283	285	317	9.86e-111	322
k141_93094_43	SARG|YP_002937728	59.3	280	285	289	2.76e-106	309
k141_93094_43	SARG|ZP_04433866	52.7	281	285	288	3.58e-99	291
k141_93094_43	SARG|ZP_03949893	52.7	281	285	288	3.58e-99	291
k141_93094_43	SARG|ZP_03984017	52.3	281	285	288	7.20e-99	290
k141_93094_43	SARG|ZP_03938934	50.0	282	285	288	8.28e-93	275
k141_93094_43	SARG|ZP_03945515	51.1	284	285	291	1.05e-91	272
k141_93094_43	SARG|ZP_03941859	49.3	282	285	288	1.35e-91	272
k141_93094_45	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	39.5	692	640	703	9.10e-145	436
k141_93286_3	CARD|gb|AFK13828.1|ARO:3000823|ramA	30.0	100	294	124	5.33e-11	58.2
k141_124911_5	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	25.2	246	535	381	4.86e-25	105
k141_124911_5	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	25.2	246	535	381	4.86e-25	105
k141_124911_5	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	24.4	234	535	381	1.80e-23	101
k141_124911_5	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	24.4	234	535	381	1.80e-23	101
k141_124911_5	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	28.8	212	535	370	7.70e-22	96.3
k141_124911_5	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	24.9	285	535	365	1.92e-20	92.0
k141_124911_5	CARD|gb|AEX49906.1|ARO:3003583|basS	24.2	236	535	477	5.34e-13	70.1
k141_124911_5	CARD|gb|ACM47284.1|ARO:3002934|vanS_in_vanD_cl	26.5	98	535	233	1.45e-06	48.5
k141_124911_5	megares|MEG_7508|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	26.5	98	535	233	1.45e-06	48.5
k141_124911_5	megares|MEG_7510|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	25.5	98	535	233	1.94e-06	48.1
k141_124911_6	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	37.6	226	227	231	9.17e-53	169
k141_124911_6	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	36.6	227	227	232	5.35e-52	167
k141_124911_6	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	37.7	228	227	232	6.05e-51	164
k141_124911_6	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	37.7	228	227	232	6.05e-51	164
k141_124911_6	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	35.4	229	227	229	1.57e-50	163
k141_124911_6	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	34.8	233	227	239	1.88e-48	158
k141_124911_6	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	36.4	228	227	231	4.23e-48	157
k141_124911_6	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	36.8	228	227	231	5.98e-48	156
k141_124911_6	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	36.4	228	227	231	5.98e-48	156
k141_124911_6	CARD|gb|ATC67679.1|ARO:3000838|arlR	32.6	224	227	219	5.99e-48	156
k141_124911_28	megares|MEG_5400|Drugs|beta-lactam|Penicillin_binding_protein|PBP2_1	24.0	571	590	633	8.52e-32	129
k141_124911_29	ResF|penA_1_AF515059_1	26.7	569	680	581	2.06e-39	152
k141_124911_29	NCBI|WP_049151672.1|1|1|pbp2m|pbp2m||2|beta-lactam|beta-lactam|penicillin-binding_protein_PBP2M|AMR|beta-lactam	26.1	291	680	593	6.64e-11	64.3
k141_204726_15	SARG|gi|445996710|ref|WP_000074565.1|	29.2	240	244	309	2.06e-21	89.7
k141_204726_15	SARG|gi|814314593|emb|CKF49145.1|	28.8	240	244	309	2.75e-20	86.7
k141_204726_15	SARG|gi|895736250|emb|COF64653.1|	28.3	240	244	309	5.24e-20	85.9
k141_204726_15	SARG|gi|446110087|ref|WP_000187942.1|	28.3	240	244	309	5.24e-20	85.9
k141_204726_15	SARG|gi|445996719|ref|WP_000074574.1|	28.3	240	244	309	7.23e-20	85.5
k141_204726_15	SARG|gi|445996709|ref|WP_000074564.1|	28.8	240	244	309	7.23e-20	85.5
k141_204726_15	SARG|gi|445996714|ref|WP_000074569.1|	28.3	240	244	309	7.23e-20	85.5
k141_204726_15	SARG|gi|895808656|emb|COR83787.1|	28.3	240	244	309	7.23e-20	85.5
k141_204726_15	SARG|gi|507044560|ref|WP_016115614.1|	28.3	233	244	306	3.49e-19	83.6
k141_204726_15	SARG|gi|445996722|ref|WP_000074577.1|	27.9	240	244	309	3.61e-19	83.6
k141_253899_8	megares|MEG_1992|Drugs|beta-lactam|Class_C_betalactamases|CMY_1	25.3	245	284	291	3.90e-08	52.4
k141_221245_2	megares|MEG_6058|Drugs|MLS|23S_rRNA_methyltransferases|RLMH_1	56.0	159	160	159	7.30e-59	179
k141_126872_6	SARG|gi|851935911|ref|WP_048224705.1|	32.2	267	331	660	9.54e-44	158
k141_126872_6	SARG|gi|1002399350|ref|WP_061382108.1|	32.2	267	331	660	9.54e-44	158
k141_126872_6	SARG|gi|851965596|ref|WP_048234849.1|	31.8	267	331	660	1.81e-43	157
k141_126872_6	SARG|gi|489117806|ref|WP_003027650.1|	31.5	267	331	660	1.81e-43	157
k141_126872_6	SARG|gi|696375142|ref|WP_032949690.1|	31.5	267	331	660	1.81e-43	157
k141_126872_6	SARG|B7LM76	31.1	309	331	660	2.49e-43	157
k141_126872_6	SARG|gi|757799830|ref|WP_043017032.1|	31.5	267	331	660	3.42e-43	156
k141_126872_6	SARG|gi|765458296|ref|WP_044714032.1|	31.1	267	331	660	3.42e-43	156
k141_126872_6	SARG|gi|489931383|ref|WP_003834702.1|	31.5	267	331	660	3.42e-43	156
k141_126872_6	SARG|YP_002850217	31.5	267	331	660	8.90e-43	155
k141_238282_15	SARG|gi|985522333|ref|WP_060811962.1|	31.2	327	331	323	1.49e-50	169
k141_238282_15	SARG|gi|498515089|ref|WP_010815296.1|	31.2	327	331	323	2.10e-50	169
k141_238282_15	SARG|Q47748	31.2	327	331	323	8.19e-50	167
k141_238282_15	SARG|gb|AAB05626.1|ARO:3002943|vanHB	31.2	327	331	323	8.19e-50	167
k141_238282_15	SARG|gi|740152780|ref|WP_037997109.1|	31.6	316	331	322	4.38e-49	166
k141_238282_15	SARG|DQ018711.1.gene4.p01	33.2	277	331	322	3.37e-48	163
k141_238282_15	SARG|YP_002333394	31.9	301	331	323	6.82e-48	162
k141_238282_15	NCBI|WP_063856701.1|1|1|vanH-B|vanH-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-B|AMR|glycopeptide	31.9	301	331	323	6.82e-48	162
k141_238282_15	SARG|AF310956.2.gene5.p01	31.9	301	331	323	9.58e-48	162
k141_238282_15	SARG|gi|737310392|ref|WP_035293250.1|	33.2	277	331	323	1.89e-47	161
k141_207339_1	megares|MEG_3790|Drugs|beta-lactam|Penicillin_binding_protein|MECA_1	35.5	549	550	666	1.54e-106	332
k141_207339_1	SARG|gi|814562231|ref|WP_046377063.1|	35.4	553	550	668	4.50e-106	331
k141_207339_1	SARG|gi|686288520|ref|WP_031860875.1|	35.3	553	550	668	8.90e-106	330
k141_207339_1	SARG|gi|909708119|ref|WP_049951317.1|	35.3	553	550	649	1.52e-105	329
k141_207339_1	SARG|gi|486697816|ref|WP_001620256.1|	35.3	553	550	668	1.76e-105	330
k141_207339_1	SARG|gi|916178542|ref|WP_050963202.1|	35.3	553	550	668	1.76e-105	330
k141_207339_1	SARG|gi|686322767|ref|WP_031876626.1|	35.3	553	550	668	1.76e-105	330
k141_207339_1	SARG|gi|686149752|ref|WP_031783696.1|	35.3	553	550	668	2.47e-105	329
k141_207339_1	SARG|AAX14397	35.3	553	550	668	2.47e-105	329
k141_207339_1	SARG|CAL22891	35.3	553	550	668	2.47e-105	329
k141_111359_5	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	38.0	216	231	307	1.78e-44	150
k141_111359_5	SARG|gi|447195835|ref|WP_001273091.1|	38.5	221	231	306	4.52e-41	141
k141_111359_5	SARG|gi|445996719|ref|WP_000074574.1|	41.4	210	231	309	4.85e-41	141
k141_111359_5	SARG|gi|542061059|gb|ERI11611.1|	37.4	219	231	316	5.70e-41	141
k141_111359_5	SARG|gi|507044560|ref|WP_016115614.1|	39.9	208	231	306	8.95e-41	140
k141_111359_5	SARG|gi|447195836|ref|WP_001273092.1|	38.0	221	231	306	1.26e-40	140
k141_111359_5	SARG|gi|445996710|ref|WP_000074565.1|	40.5	210	231	309	1.35e-40	140
k141_111359_5	SARG|ZP_04081918	38.0	221	231	306	1.77e-40	139
k141_111359_5	SARG|gi|445996724|ref|WP_000074579.1|	41.0	210	231	309	1.90e-40	139
k141_111359_5	SARG|gi|445996722|ref|WP_000074577.1|	41.0	210	231	309	1.90e-40	139
k141_111359_14	SARG|gi|500448961|gb|EOP61695.1|	38.6	210	216	306	1.10e-40	139
k141_111359_14	SARG|gi|500465078|gb|EOP76697.1|	38.6	210	216	306	1.10e-40	139
k141_111359_14	SARG|gi|447195835|ref|WP_001273091.1|	38.6	210	216	306	1.54e-40	139
k141_111359_14	SARG|P42332	38.1	210	216	306	3.06e-40	138
k141_111359_14	SARG|ZP_04081918	38.1	210	216	306	3.06e-40	138
k141_111359_14	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	38.1	210	216	306	3.06e-40	138
k141_111359_14	SARG|gi|510143239|gb|AGN36970.1|	38.1	210	216	313	3.59e-40	138
k141_111359_14	SARG|gi|447195836|ref|WP_001273092.1|	38.1	210	216	306	4.30e-40	138
k141_111359_14	SARG|ABB80128	38.1	210	216	306	6.05e-40	137
k141_111359_14	SARG|gi|542061059|gb|ERI11611.1|	35.7	210	216	316	7.58e-40	137
